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ABSTRACT 
 
 
 Hepatocellular carcinoma (HCC) is the 2nd leading cause of cancer-related death 
worldwide and the leading cause of death among patients with cirrhosis. HCC screening is 
highly recommended by professional societies to improve early tumor detection and survival, but 
is underused in clinical practice.  
 This dissertation addresses gaps in the current literature concentrated on HCC screening 
and specifically focuses on three areas: (1) two improved approaches to measure HCC screening 
using administrative data, (2) the impact of patient and provider factors on HCC screening, and 
(3) the impact of HCC screening on early tumor detection and overall survival. 
 The first study in this dissertation explores two improved approaches to measure HCC 
screening using a linkage of two large population-based sources of data and subsequently 
characterizes HCC screening rates over time using these measures. Receipt of HCC screening 
was characterized using: (a) mutually exclusive categories (consistent vs. inconsistent vs. no 
screening), and (b) proportion of time up-to-date (PUTD) with screening. Most (51.1%) patients 
did not receive any screening in the 3 years prior to HCC diagnosis, and 13.4% of patients 
underwent timely, consistent screening annually (PUTD). 
 The second study in this dissertation identifies patient and provider factors that influence 
HCC screening receipt using the PUTD measure. Patient and provider predictors for HCC 
screening were assessed using a multivariate two-part regression. Receipt of any HCC screening 
was associated with younger patient age, female gender, Asian race, longer length of time with 
known cirrhosis, presence of more than one liver correlated condition, presence of hepatic 
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encephalopathy, higher comorbidity score and having visited a gastroenterologist (p<0.001). 
 The third and final study in this dissertation evaluates the association between HCC 
screening receipt and clinical outcomes, including: (a) early tumor detection and (b) overall 
survival using multivariate logistic regression and Cox proportional hazards model, respectively. 
Receipt of consistent screening was associated with early tumor detection (OR 2.10; 95% CI 
1.79-2.47) and improved survival (HR 0.72, 95%CI 0.66 – 0.78). 
 The findings of this dissertation highlight potential areas for intervention including 
improved awareness and education regarding HCC screening for patients and providers. 
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1. INTRODUCTION 
 
Liver cancer is the 2nd leading cause of cancer-related death worldwide for men and 
women combined.1 Hepatocellular carcinoma (HCC), the most common type of primary liver 
cancer, is the leading cause of death among patients with cirrhosis. Although HCC is the 9th 
leading cause of cancer-related death in the U.S., its incidence has tripled over the last 30 years.2–
5 It is projected to surpass breast and colorectal cancer to become the 3rd leading cause of cancer-
related death in the United States by 2030.6–12 In 2013, 21,143 men and 8,330 women were 
diagnosed with liver cancer, and 16,300 men and 7,732 women died of liver cancer.13 
While death rates for most cancer sites have been declining in the United States from 
2003 to 2012, for both men and women of all major racial and ethnic groups, deaths from liver 
cancer have continued to increase over the same period by an average of 3% per year.5 There are 
prominent gender, racial/ethnic, socioeconomic, and geographic disparities for HCC incidence 
and mortality.1,14–16 For example, recently HCC incidence rates were found to be the highest 
among American Indians/Alaskan Natives, followed by Asian Pacific Islanders and Hispanics.1 
Other studies have found HCC incidence and mortality to be the highest among Hispanics and 
African Americans than non-Hispanic Caucasians and higher in patients of low socioeconomic 
status (SES).7,16–22 Although studies in literature have postulated biological differences, others 
believe disparities can be largely attributed to differences in the delivery of HCC screening and 
treatment. 
Hepatocellular carcinoma (HCC) screening is recommended by professional societies to 
improve early tumor detection and survival, but is underused in clinical practice.22–25 HCC 
prognosis depends on tumor stage at the time of diagnosis, with curative treatment options only 
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available for patients diagnosed at an early stage.19,23 Patients with early stage HCC can achieve 
5-year survival rates of 70% if they undergo surgical resection or liver transplantation, compared 
to 1-year for patients with advanced HCC.26 Given data from a large randomized controlled trial 
(RCT) and several cohort studies demonstrating a potential survival benefit associated with early 
tumor detection, society guidelines from the American Association for the Study of Liver 
Diseases (AASLD) and National Comprehensive Cancer Network (NCCN) recommend HCC 
screening in high-risk patients, including those with cirrhosis.11,19,20,23,27  
HCC screening is a complex, multifaceted process that poses many unique challenges.23 
The effectiveness of proper HCC screening is crucial and contingent upon delivery of care in a 
multilevel healthcare system, all which may be susceptible to failure. Factors such as insurance 
coverage and access to a tertiary care center at the patient-level, knowledge of guidelines and 
risk assessment at the provider-level, availability of screening tests, and ability to schedule 
appointments in a timely manner at the system-level are all noteworthy barriers to effective HCC 
screening.28 Unfortunately, prior studies suggest less than 20% of patients with cirrhosis receive 
HCC screening.19,20,22,23,29 Therefore, many patients with HCC are diagnosed at an advanced 
stage, when they are no longer eligible for curative treatment.  
It is crucial to understand the several major risk factors or causes of HCC to properly 
identify the at-risk patient population that should undergo routine HCC screening. The number 
one risk factor for HCC is liver cirrhosis.30–33 Liver cirrhosis or simply cirrhosis is defined as late 
stage of scarring (fibrosis) of the liver.34 It is caused by many conditions such as hepatitis and 
chronic alcoholism and have affected 3.9 million Americans as of 2016.34,35 In some instances, 
HCC can occur in the absence of cirrhosis, however cirrhosis is typically present in 80% to 90% 
of patients with HCC.11 Early diagnosis of liver cirrhosis is very important in order to manage 
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chronic liver disease, however patients with compensated cirrhosis are often asymptomatic and 
thus cirrhosis may remain unrecognized for many years.33,36–38 A study by Walker et al. found 
24.6% of patients in a random sample of HCC cases in the national Veterans Affairs (VA) 
system had unrecognized cirrhosis prior to HCC diagnosis.37 
Other major HCC etiologic risk factors for HCC include infection with hepatitis B virus 
(HBV) or hepatitis C virus (HCV).11 Both HBV and HCV are different virus structures, however 
both use common pathways to induce hepatocarcinogenesis or the production of cancer in the 
liver.39 Worldwide, prevalence of HBV is highest in Asian countries.4,40 Approximately 1.25 
million Americans have HBV infection and it is especially common among Asians. The high 
rates of HBV infection in the United States can be attributed to immigration patterns in this racial 
group.41 HBV can cause chronic liver infection that can later develop into cirrhosis or HCC.40 In 
HCV infection, the risk of developing cirrhosis is between 15% to 30% within 20 years.42 
Consequently, the risk of developing HCC for a patient with HCV-related cirrhosis is 
approximately 2% to 6% per year.43–45 
Alcoholic fatty liver and alcoholic cirrhosis is related to heavy alcohol consumption.4,11,46 
Alcoholic fatty liver is a result of acute alcohol ingestion and risk of liver disease increases with 
the quantity and duration of alcohol intake.46 As a result, alcoholic cirrhosis can develop and 
subsequently progress into HCC.4,14 In a recent study at Mayo Clinic, alcohol consumption was 
the most common cause of cirrhosis (32%).47 
Other risk factors for HCC that are less common include hereditary hemochromatosis 
(excess iron), alpha1-antitrypsin deficiency (inherited disorder that may cause lung disease and 
liver disease), autoimmune hepatitis, some porphyria (disorders resulting from buildup of certain 
chemicals related to red blood cell proteins), and Wilson’s disease (inherited disorder that causes 
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too much copper to accumulate in the organs).11 Risk factors for HCC are summarized below in 
Figure 1. 
 
Figure 1. Summary of risk factors for the development of liver cirrhosis and subsequent HCC 
 
This diagram illustrates the contributing risk factors for the development of liver cirrhosis and HCC. 
 
1.1 Overview of the Dissertation and Conceptual Framework 
This dissertation: 1) explores improved approaches to measure HCC screening in 
administrative data and characterizes utilization of HCC screening receipt; 2) examines the 
impact of patient and provider factors on screening receipt; and 3) analyzes the association 
between early tumor detection related to screening and patient survival. Each of these studies in 
this dissertation focuses on the same sample of patients drawn from population based cancer 
registries in the United States, and each study builds on the preceding study. 
Figure 2 illustrates how each analysis is tied to one another, as well as its relation to the 
importance of HCC screening in at risk patients. This conceptual model is developed using the 
Quality in the Continuum of Cancer Care (QCCC) conceptual framework and contextual 
characteristics from the Andersen Behavioral Model of Utilization (“Anderson model”).48–52 This 
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dissertation study builds on the understanding of how predisposing and enabling factors 
influence transitions in cancer care for HCC patients, specifically receipt of HCC screening and 
the effects of early tumor detection and overall survival.  
The QCCC conceptual framework provides a systematic approach for assessing factors 
that influence types of cancer care and the transitions between them, including the factors at 
several levels of care in a multilevel healthcare system that potentially impact access and 
quality.51 The QCCC framework highlights four important aspects in cancer care: a) to 
emphasize the relationship of services and processes of care to outcomes; b) to identify the 
potential for failures in between and during key types of care; c) to consider the complex 
environmental factors that impact care; and d) to suggest strategies available to plans, organized 
health systems, and medical practices to improve performance.51 
The Andersen model describes the underlying social and enabling factors that may lead 
to inequitable access to care.53,54 Both models are integrated to describe the characteristics that 
may influence failures in cancer care for HCC. Failures in cancer care fall into two categories: a) 
breakdowns in specific types of care delivered to individuals at different points in the history of 
their cancer; and b) breakdowns during the transitions between these types of care.51 This study 
will further identify factors in the complex care processes that contribute to the shortcomings in 
the transitions of screening for at risk HCC patients. 
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Figure 2. Conceptual framework of underlying and enabling factors for HCC patients in 
transitions of care 
 
Adapted from Taplin & Rogers 2010 50, Zapka et al. 2003 51, Andersen & Newman 1973 54 
This conceptual model illustrates how each study in this dissertation is interrelated. 
 
It is important to understand the complex contextual and environmental factors that affect 
utilization of HCC screening, processes of care, and ultimate outcomes.51,53 Using both the 
QCCC conceptual framework and contextual characteristics from the Andersen model, this 
dissertation will increase the understanding of patient and provider factors that contribute to 
unmet and delayed HCC screening receipt, as well as HCC screening impact on early tumor 
detection and overall survival. Further, the following subsections describe each focus area in 
greater detail. 
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1.1.1 Measurement of HCC Screening Using Administrative Data 
In previous literature, HCC screening has been typically defined as mutually exclusive 
categories (consistent or regular vs. inconsistent vs. no screening).55 A study by Davila and 
colleagues define regular screening as having had an annual AFP and/or ultrasound test during at 
least 2 of the 3 years prior to HCC diagnosis and inconsistent screening as having had one or 
more AFP or ultrasound tests for screening purposes during the 3 years prior to HCC diagnosis.55 
Arguably, this measurement to characterize consistent and inconsistent HCC screening does not 
reflect the recommended HCC screening guidelines of the American Association for the Study of 
Liver Diseases (AASLD) and National Comprehensive Cancer Network (NCCN) to perform 
ultrasound-based screening at 6-month intervals. The first study of this dissertation adds to the 
current literature and suggests more meaningful measures to determine HCC screening 
utilization using administrative data. 
 This study builds on the same previously developed mutually exclusive categories 
(consistent vs. inconsistent vs. no screening), however consistent screening was defined as 
having ≥1 abdominal ultrasound per calendar year, and inconsistent screening was defined as 
having ≥1 abdominal ultrasound during the study period, but less than annually. Conversely, 
some providers have reported that this measure using secondary data is not as clinically useful in 
determining the impact of HCC screening and its subsequent effects on referrals to various 
specialty providers, receiving timely treatment and survival. A proportion of time up-to-date with 
screening (PUTD) measure, where patients had received screening during the proportion of the 
36-month study period, was adapted from pharmacy literature as a more clinically meaningful 
way to capture more details and measure patient utilization of HCC screening. 
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1.1.2 Impact of Patient and Provider Factors on HCC Screening 
HCC screening is highly dependent upon multiple levels of contextual influence, 
including factors at the patient-level, provider-level, system-level, local community environment, 
and state and national policy.28,49 Clinical decision making varies according to these 
characteristics.56 The theory of complex adaptive systems suggests that interactions between 
people and levels travel in multiple directions and individuals and layers within the system are 
therefore continuously adapting.57 In addition, influences between contextual levels may not be 
completely hierarchial.49 Based off these theories, the second study of this dissertation seeks to 
identify factors that may influence HCC screening receipt, as well as understand variations in 
HCC care delivery by building on the QCCC conceptual framework and the Andersen 
model.49,58–60  
 The target levels of this dissertation are specifically the individual patient (including 
biological and social risk factors) and the provider (including specialty and training skills) since 
patient and provider level factors are centrally nested in these aforementioned contextual levels 
of human aggregation.49,58,59 Individuals seeking, receiving and providing cancer care (the 
individual patient and the provider) are two substantial forces in health behavior that may 
eventually result in improved patient and population outcomes.49 Thus, the individual patient and 
provider are greatly influential in the complex delivery of HCC screening.49 
1.1.3 Impact of HCC Screening on Early Tumor Detection and Survival 
HCC prognosis depends on tumor stage at the time of diagnosis and curative treatment 
options are only available for patients diagnosed at an early stage.19,23 Patients with early stage 
HCC can achieve 5-year survival rates of 70% if they undergo surgical resection or liver 
transplantation.26 Therefore, HCC screening is imperative in order to detect HCC at an early 
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stage, so that these curative treatment options can be applied.  Unfortunately, studies in literature 
report that HCC screening receipt is heavily underutilized.12,22,47,55,61 Thus, many patients with 
HCC are diagnosed at an advanced stage, when they are no longer eligible for curative treatment. 
Most studies in literature were conducted at single centers and prior multi-center studies 
were published several years ago, which may no longer reflect current practice. To evaluate the 
effects of HCC screening in more recent years, the third and final study of this dissertation 
characterizes the association of HCC screening with early tumor detection and survival in a large 
population based sample. 
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2. MEASUREMENT OF HCC SCREENING USING ADMINISTRATIVE DATA 
 
2.1 Introduction 
HCC screening is recommended by professional societies to improve early tumor 
detection and survival, but is underused in clinical practice. The American Association for the 
Study of Liver Diseases (AASLD) recommends ultrasound with or without alpha-fetoprotein 
(AFP) at 6-month intervals for high-risk populations to monitor the potential development of 
HCC.12 HCC screening has been defined as mutually exclusive categories (consistent or regular 
vs. inconsistent vs. no screening) in prior studies in literature, where regular screening was 
having had an annual AFP and/or ultrasound test during at least 2 of the 3 years prior to HCC 
diagnosis and inconsistent screening was defined as having had one or more AFP or ultrasound 
tests within 3 years prior to HCC diagnosis. Debatably, this measurement does not properly 
reflect the recommended HCC screening guidelines given by the American Association for the 
Study of Liver Diseases (AASLD) and National Comprehensive Cancer Network (NCCN). 
These societies recommend ultrasound-based screening for HCC at 6-month intervals in at risk 
patients, and therefore these definitions defined in prior literature are not rigorous enough. 
Instead, this study builds off this mutually exclusive HCC screening classification where 
consistent screening is defined as having ≥1 abdominal ultrasound per calendar year, and 
inconsistent screening was defined as having ≥1 abdominal ultrasound during the study period, 
but less than annually. In addition, some providers have stated that this mutually exclusive 
categorical measure may not be as clinically useful in determining the impact of HCC screening 
on various stages of cancer care such as referrals to various specialty providers, receiving timely 
treatment and subsequent survival. Therefore, a proportion of time up-to-date with screening 
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(PUTD) measure, where patients had received screening during the proportion of the 36-month 
study period, was proposed and developed as a more clinically meaningful way to measure 
frequency of HCC screening given the American Association for the Study of Liver Diseases 
(AASLD) and National Comprehensive Cancer Network (NCCN) recommend screening at 6-
month intervals for at risk patients. 
The first study of this dissertation adds to the current literature and suggests improved 
alternate measurements for HCC screening utilization based off society guidelines from the 
American Association for the Study of Liver Diseases (AASLD) the and National 
Comprehensive Cancer Network (NCCN) using a large population based administrative data. 
Background 
Screening for HCC is extremely unique compared to other cancers in that radiological 
tests are standard due to well-defined imaging criteria. As previously mentioned in this study, 
Davila and colleagues defined a mutually exclusive categorical variable (consistent or regular vs. 
inconsistent vs. no screening) where regular consistent screening was defined as having had an 
annual AFP and/or ultrasound test during at least 2 of the 3 years prior to HCC diagnosis and 
inconsistent screening as having had one or more AFP or ultrasound tests for screening purposes 
during the 3 years prior to HCC diagnosis.55 
Since it was first discovered in 1964, AFP has been noted as the most useful serum 
biomarker to detect HCC.62 Previous studies in literature have indicated that AFP determination 
lacks sensitivity and specificity for effective HCC screening and for diagnosis.31,63–65 HCC was 
only positive for the protein in only 60% to 80% of cases, and false-positives made it challenging 
to characterize early stage HCC from other disorders including acute hepatitis and cirrhosis and 
certain gastrointestinal tumors.62 These outcomes as a result question AFP as a dependable 
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biomarker.62 Given this study defined regular screening to be receipt of annual “AFP and/or 
ultrasound” during 2 of the 3 years prior to HCC diagnosis, it is arguable that this study is not 
precise enough given this study included patients having received solely an AFP test as adequate 
screening.55 
In addition to using solely AFP determination for HCC screening, this measurement is 
not adequate and does not reflect the recommended frequency of HCC screening in at risk 
patients in the clinical setting. Davila and colleagues defined regular HCC screening as receipt of 
either test during 2 of the 3 years prior to HCC diagnosis. Given AFP determination lacks 
sensitivity and specificity, consistent or regular screening should be defined as having an 
abdominal ultrasound twice annually and therefore patients at risk should receive approximately 
6 abdominal ultrasounds, or at least 3 during the screening period. Actual rates of HCC screening 
in literature are hypothesized to be overestimates, as these measurements for HCC screening 
utilization are not rigid and do not reflect guidelines from professional societies. 
A screening interval of 6-months has been shown to have greater benefits, including 
survival in comparison to a screening interval of 12-months.66 Studies also noted a screening 
interval at 3-months was not superior to 6-months given the low sensitivity. Screening more 
frequently at 3 months increased the detection of small focal lesions, but not HCC.66 There were 
no differences in cumulative incidence of HCC, or prevalence of lesions >30mm in a multi 
center randomized trial from Europe.67 
Therefore, recommended HCC screening should be based on at least ultrasound 
examination and should be ordered by a provider every 6 months for patients at risk, in 
accordance to the American Association for the Study of Liver Diseases (AASLD) and National 
Comprehensive Cancer Network (NCCN).22,23,30,68  
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Cancer Staging 
Cancer staging for HCC is used to determine how advanced a tumor is (the size, whether 
the tumor has spread, and if so, how far) in a patient, as well as prognosis.86,87 More importantly, 
cancer staging for HCC is used as a guiding tool to assess whether a patient is eligible for 
curative treatments (liver transplantation, resection or ablation), or whether the patient should be 
referred to noncurative treatments (chemotherapy, sorafenib, radiation).86–90 Patients diagnosed 
with HCC at an early stage are characteristically eligible for curative treatments.12,20,23,61,68,90 
There are countless tumor staging systems for HCC, but currently, there is no single, 
universal “gold standard” tumor staging system for HCC.86,87 There are 6 well established 
staging systems that are commonly used in clinical practice to determine early stage HCC and 
eligibility for curative treatments. Some of the following tumor staging systems are utilized more 
often than others in various parts of the world.86 The following established staging systems are: 
 
1) TNM staging system 
2) Okuda staging system 
3) Cancer of the Liver Italian Program (CLIP) staging system 
4) Barcelona Clinic Liver Cancer (BCLC) staging system 
5) University of California, San Francisco (UCSF) staging system 
6) Milan Criteria 
 
Other tumor staging criteria for HCC include the Chinese University Prognostic Index 
(CUPI), the Japan Integrated Staging (JIS) score, the Liver Cancer Study Group of Japan 
(LCSGJ), the Hong Kong Liver Cancer classification, the Taipei Integrated Score System, the 
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Dallas Criteria, Asian Criteria, Kyoto Criteria, Kyushu University Criteria, and the Toronto 
Criteria.87,91  
The American Joint Committee on Cancer (AJCC) uses a standard tumor-node-metastasis 
(TNM) system criteria for many cancers, including HCC, to predict prognosis.87,92 
Unfortunately, this staging criterion has limitations, since it does not take into account the 
unique, complex biological behavior of HCC given most patients with HCC also have extensive 
damage to the liver.86 Further, the TNM staging system only evaluates tumor extension and does 
not take into account the degree of liver dysfunction and patient performance in staging, which 
suggests this staging criterion is not sufficient. There is immense heterogeneity regarding patient 
characteristics and HCC biology, which would deem other tumor staging systems developed 
specifically for HCC to be more suitable.89 
The Okuda staging system was developed in 1985 by Okuda et al. during a time when 
almost all HCC cases were diagnosed at an advanced stage.87 The Okuda staging system is based 
on tumor load (number of cancer cells, size of tumor or amount of cancer in body), ascites, and 
albumin and bilirubin blood levels, however this classification is outdated and does not properly 
identify patients who may be eligible for curative treatments.87,89,93,94 
The Cancer of the Liver Italian Program (CLIP) is defined using Child-Pugh score, 
distribution of tumor(s), AFP level, and portal vein thrombosis.87 Child-Pugh score is the 
cirrhosis staging system, but is also used often in clinical practice to determine whether a patient 
may be eligible for curative treatments.87,95 The Child-Pugh score measures liver function based 
on ascites, albumin and bilirubin blood levels, as well as prothrombin (clotting) time and brain 
function.86,87,95 The CLIP criteria exhibited greater predictive power than the Okuda staging 
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system in one study, however some studies in literature revealed that other tumor staging 
systems were superior in predicting prognosis in patients.87,89,94 
The Barcelona Clinic Liver Cancer (BCLC) is not a scoring system, but rather a 
classification tool aimed at improving prognosis assessment for patients. The BCLC also serves 
as a guiding instrument to determine appropriate treatments for HCC.96 The BCLC was based off 
of several cohort studies and randomized control trials (RCT)s and is defined using tumor size, 
number of tumors, and portal vein thrombosis and utilizes Child-Pugh scores.89 The BCLC 
criteria is unique in that it links the stage of HCC to a specific treatment strategy.94 The BCLC is 
the most widely validated and accepted staging system; it has been incorporated into professional 
society guidelines including AASLD and EASL guidelines.  
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Figure 3. Barcelona Clinic Liver Cancer (BCLC) staging classification and treatment schedule 
 
This figure is adapted from Llovet et al. and illustrates a flow diagram describing the Barcelona Clinic 
Liver Cancer (BCLC) staging classification and appropriate treatment schedule.96 
 
However, the BCLC also has some limitations.92 Stage B (intermediate stage) of BCLC, 
includes a very diverse population of HCC patients who have wide-ranging degrees of tumor 
extension, liver functional reserve and disease etiology.91,97 This imprecision causes the 
determination of optimal treatment for HCC to be difficult.88,94 Further, the one-to-one 
correspondence treatment recommendations for each stage of BCLC may not be applicable in 
clinical practice settings.88 
Other criteria for early stage tumors for HCC include the University of California, San 
Francisco (UCSF) criteria.98 The University of California, San Francisco (UCSF) criteria is 
defined as a single tumor <6.5cm, or a maximum of 3 total tumors <4.5cm or a cumulative tumor 
size of <8cm.98,99 Many transplant centers worldwide utilize the UCSF criteria as the standard 
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selection liver transplantation criteria for HCC.100 Yao and colleagues at UCSF reported a 5-year 
post liver transplantation survival of 75% in patients with tumors as large as 6.5cm and a 
cumulative tumor burden ≤8cm.99 However, this study and subsequent criteria has been 
challenged due to small sample size.98 
The Milan Criteria is the most prominent and conservative criteria for early stage tumors 
for HCC. The tumor staging indicator used to determine eligibility for liver transplantation is 
highly stringent compared to other staging systems. In the U.S., Medicare approves liver 
transplantations for patients with HCC who only meet Milan Criteria.98 Although some 
investigators have argued that the Milan Criteria is too restrictive, studies in literature have 
shown that patients within Milan Criteria benefit the most from liver transplantation and have 
excellent outcomes.26,91,98–101 In one study, survival for patients within Milan Criteria exceeded 
50% at 5 years compared to below 50% for patients within UCSF criteria.98 Recurrent-free 
survival was 74% for patients within Milan Criteria, and 65% for patients within UCSF Criteria 
at 5 years post liver transplantation.98  
2.2 Methods 
2.2.1 Data Source 
A retrospective, descriptive study using the Surveillance, Epidemiology and End Results 
(SEER)-Medicare data was conducted. Linked SEER-Medicare data combines clinical, 
demographic and survival information for persons with cancer from the SEER program of cancer 
registries with Medicare claims information on covered health services from time of Medicare 
eligibility until death.  
The SEER program collects data on incident cancer cases from 20 cancer registries, 
including state, central, metropolitan, and the Alaska Native registries.69–71 These areas account 
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for approximately 28% of the population in the United States.69,72 Medicare is the primary health 
insurer for approximately 97% of individuals ages 65 years and older and roughly 95% of 
Medicare beneficiaries are covered by both Part A (inpatient hospitalizations) and Part B 
(outpatient visits and physician office visits/services) benefits.55 Although a majority of people 
were covered by traditional Medicare, approximately 13% of people were enrolled in a Medicare 
Advantage plan in 2003 and this increased to 28% in 2013.73 
Many files are encompassed in the SEER-Medicare data. The primary file titled, SEER 
Patient Entitlement and Diagnosis Summary File (PEDSF file) contains one record per patient 
for cancer cases in the SEER database and holds information on patient and tumor 
characteristics, as well as Medicare eligibility and enrollment.72 Non-cancer cases are also 
available in the Summarized Denominator (SUMDENOM) File.74 The "non-cancer" group is 
acquired from a random 5 percent sample of Medicare beneficiaries residing in the SEER 
areas.72,74 Information from the non-cancer group can be used for comparative studies, including 
comparative effectiveness research on use of specific tests or procedures or case control 
studies.72,74 Given this study focused only on patients diagnosed with HCC, we did not obtain the 
Summarized Denominator (SUMDENOM) File. 
There are 7 Medicare claims files for Medicare beneficiaries with Fee-For-Service (FFS) 
coverage.75 These 7 files are listed below: 
 
1) Medicare Provider Analysis and Review (MEDPAR) 
2) Carrier Claims (old file name Physician/Supplier Part B (NCH)) 
3) Outpatient Claims 
4) Home Health Agency (HHA) 
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5) Hospice 
6) Durable Medical Equipment (DME) 
7) Medicare Part D Data 
 
The Medicare Provider Analysis and Review (MEDPAR) file includes all Part A short 
stay, long stay, and skilled nursing facility (SNF) bills for each calendar year.75 The file contains 
one summarized record per admission and each record contains up to 25 ICD-9 diagnoses and 25 
ICD-9 procedures recorded during the hospitalization.75 The Carrier Claims (NCH) file contains 
physician/supplier (Part B) bills for 100 percent of all claims, specifically these bills are largely 
from physicians.75 However, the file can also include claims from other non-institutional 
providers such as physician assistants, clinical social workers, nurse practitioners, independent 
clinical laboratories, ambulance providers, and stand-alone ambulatory surgical centers.75 Each 
ICD-9 diagnosis code is supplemented with a HCPCS code in the claim. The Outpatient Claims 
file contains Part B claims from institutional outpatient providers.75 Examples of institutional 
outpatient providers include ambulatory surgical centers, hospital outpatient departments, rural 
health clinics, renal dialysis facilities, outpatient rehabilitation facilities, comprehensive 
outpatient rehabilitation facilities, and community mental health centers. Similar to the Carrier 
Claims file, each ICD-9 diagnosis code is supplemented with a HCPCS code in the claim.75 
The Home Health Agency (HHA) file includes 100 percent of all claims for home health 
services, including skilled-nursing care, home health aides, physical therapy, speech therapy, 
occupational therapy, and medical social services visits.75 The Home Health Agency (HHA) file 
also includes information on ICD-9 diagnosis.75 Similarly, the Hospice file contains information 
on claims data submitted by Hospice providers and can include information on the terminal 
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ICD-9 diagnosis.75 The Durable Medical Equipment (DME) includes information on claims 
data submitted to the Durable Medical Equipment Regional Carriers (DMERCs) for items such 
as wheelchairs (manual and electric), hospital beds, traction equipment, canes, crutches, 
walkers, kidney machines, ventilators, oxygen, etc.75 Lastly, the Medicare Part D Data file 
includes information beginning with 2007 regarding Medicare beneficiaries enrolled in Part D, 
dates of coverage, as well as drug utilization.75 
Medicare claims files used for this study included the Medicare Provider Analysis and 
Review (MEDPAR), Carrier Claims (NCH), Outpatient Claims and Medicare Part D Data files 
given the goal of the study was the characterize HCC screening using abdominal ultrasounds in 
patients already diagnosed with HCC. Therefore, only claims surrounding ICD-9 and HCPCS 
procedure codes related to the potential screening, diagnosis, and treatment surrounding HCC 
were needed for this study.  
Since this study did not involve information related to claims for home health services, 
including skilled-nursing care, home health aides, physical therapy, speech therapy, occupational 
therapy, and medical social services, hospice care, or durable medical equipment, the Home 
Health Agency, Durable Medical Equipment and Hospice files were excluded from use in this 
study. 
All data construction and analyses were conducted using STATA 14.0 (StataCorp, 
College Station, TX, USA) and SAS 9.4 (SAS Institute Inc., Cary, NC). The study protocol was 
approved by the Institutional Review Board of Texas A&M University and the Office of the 
National Cancer Institute (NCI), Division of Cancer Control & Population Sciences. 
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2.2.2 Study Population 
All HCC Patients 
All Medicare beneficiaries, aged 65 years and older, who have been diagnosed with HCC 
(International Classification of Disease-Oncology (ICD-O) code 8170) from the years of 2003 to 
2013 in the sample were included.76 Only patients with diagnostically confirmed HCC (positive 
histology, cytology, laboratory test/marker, positive radiology tests) in the SEER data were 
eligible for inclusion. Patients with Medicare Part A and B enrollment less than 3 years prior to 
HCC diagnosis, patients enrolled in Medicare health maintenance organizations (HMOs), and 
patients with missing tumor characteristics were excluded from the sample.55,71 Patients enrolled 
in Medicare health maintenance organizations (HMOs) were excluded since these plans were not 
required to submit individual claims information for services to the Centers for Medicare and 
Medicaid Services (CMS).55,71 
Known Cirrhosis Subsample 
Patients with cirrhosis were identified using ICD-9 codes (571.2, 571.5, or 571.6) from 
Medicare claims (MEDPAR, NCH, Outpatient files).55,77 Patients who had their first cirrhosis 
diagnosis before the 3-year screening period were identified as patients with known cirrhosis. In 
order to determine this subsample, the first diagnosis of cirrhosis was identified for each patient 
using the first claim date that was billed for any diagnosis for cirrhosis using the “from date” 
found in Medicare claims (MEDPAR, NCH, Outpatient files).  
If patients had no ICD-9 code for cirrhosis, these patients were then reviewed for any 
evidence of decompensated cirrhosis. Patients with decompensated cirrhosis were also identified 
from Medicare claims data (MEDPAR, NCH, Outpatient files), as these patients essentially had 
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cirrhosis and should be included in the subsample. Evidence of decompensated cirrhosis include 
variceal gastrointestinal bleeding, ascites and hepatic encephalopathy.33 Variceal gastrointestinal 
bleeding is typically caused by cirrhosis, which is dilated veins in the distal esophagus or 
proximal stomach caused by elevated pressure in the portal venous system.33,38 Ascites is defined 
as accumulation of fluid in the abdomen and is the most common manifestation of 
decompensated cirrhosis.33 Hepatic encephalopathy is the neuropsychiatric abnormalities and 
impairment of intellectual and neuromuscular function as a result of liver insufficiency.33  
In order to determine patients who had decompensated cirrhosis, patients who had any 
diagnosis for ascites (ICD-9 789.51, 789.59) or any pharmacy claims billed for spironolactone or 
furosemide from the Medicare Part D Data file was considered as having a diagnosis of cirrhosis. 
Similarly, if patients had a diagnosis for hepatic encephalopathy (ICD-9 572.2) or any pharmacy 
claims for lactulose and rifaximin, then that patient was evident of having cirrhosis. The generic 
drug name “GNN” variable was used to identify these medications. The first claim date that was 
billed for any diagnosis for ascites or hepatic encephalopathy was used as a proxy date for the 
first date of diagnosis of cirrhosis. Patients that had a first date of ascites or hepatic 
encephalopathy before the start of the 3-year screening period were categorized into the known 
cirrhosis subsample. There were 2,972 HCC patients with known cirrhosis. Of these HCC 
patients, 2,567 patients had a diagnosis of cirrhosis and 405 patients had decompensated 
cirrhosis prior to the 3-year screening period. 
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Figure 4. Flow diagram of patient sample selection 
 
This diagram illustrates the sample selection for this study. 
 
2.2.3 HCC Screening Definition 
Categorical HCC Screening Measure 
In order to compare HCC screening utilization rates in recent years with rates from 
previous studies in prior years, a mutually exclusive categorical variable was constructed similar 
to prior studies, however screening categories were established to reflect society guidelines as 
previously mentioned. The first constructed measure was defined as: 1) consistent screening 2) 
inconsistent screening and 3) no screening. Consistent screening was defined as having ≥1 
abdominal ultrasound per calendar year to take into consideration the American Association for 
the Study of Liver Diseases (AASLD) and National Comprehensive Cancer Network (NCCN)’s 
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recommendation for HCC screening at 6-month intervals. Inconsistent screening was then 
defined as having ≥1 abdominal ultrasound during the study period, but less than annually in this 
study. A more liberal definition is used given extremely low rates of semiannual screening 
(<1%).23,29,68 A buffer for this measure was not used since screening every 12 months was 
already considered a conservative definition for consistent screening.  
It is important to note that this categorical measure was included in this dissertation in 
order to properly compare HCC screening rates with previous studies in the literature.47,78 
Continuous HCC Screening Measure 
Some providers have expressed that categorizing HCC screening receipt into groups does 
not provide much information regarding the extent of utilization of HCC screening.22,23,47 To 
improve measurement of HCC screening utilization using administrative data, a continuous 
measure was also defined as the proportion of the 36-month study period in which patients had 
received screening, with each abdominal ultrasound providing 7 months of screening coverage. 
Given 6 months of screening is recommended, 7 months was chosen for this measure to account 
for a 1-month buffer. For example, if a patient was diagnosed with HCC in April 2011, and only 
received an abdominal ultrasound in January 2009 and a second one in July 2010 during the 
entire screening period, then this patient only had 14 months of screening coverage in the 36-
month study period or a PUTD of 0.39. This example is depicted below in Figure 4. Patients 
could also have overlapping ultrasounds, meaning the 7-month coverage could be shorten by the 
second ultrasound. For example, if a patient only received an abdominal ultrasound in January 
2009, and the second one in March 2009, then this patient during the entire 36-month study 
period, then the patient only had 9 months of screening coverage, or a PUTD of 0.25. 
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The continuous measure was an applied methodology concept from pharmacy literature, 
specifically in research surrounding medication adherence, in order to capture more details of 
HCC screening receipt.79,80 This PUTD measure would be useful in helping to distinguish 
patients who received timely HCC screening every 6 months compared to patients who were late 
or non-adherent and had gaps in screening care. The previously mentioned mutually exclusive 
categorical variable would not be able to identify these screening gaps, and also does not have 
the potential to assess how often these gaps are occurring and for how long. Although grouping 
may help data presentation and allow for easier interpretation of results, it can be seen as an 
extreme form of rounding resulting in a loss of information and power.78,81 Dichotomizing or 
categorizing variables that can be continuous would reduce the correlation with the true 
values.78,81  
Inferences resulting from the proportion of time up-to-date with screening (PUTD) 
measure would allow for higher sensitivity in future regression analyses and would also offer 
precision measurement, and subsequently better insight in sources of variation for HCC 
screening.78 The proportion of time up-to-date with screening (PUTD) measure would 
additionally reflect the American Association for the Study of Liver Diseases (AASLD) and 
National Comprehensive Cancer Network (NCCN)’s recommendation for HCC screening at 6-
month intervals. 
For both measures, receipt of an abdominal ultrasound was identified using the current 
procedural terminology (CPT) codes 76700 and 76705 using the “from date” in Medicare claims 
files (NCH and Outpatient files).75  
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Figure 5. Measurement for PUTD with screening 
	
This diagram illustrates the calculation for the proportion of time up-to-date with screening (PUTD) 
measure. 
 
2.2.4 Validated HCC Screening Algorithm 
In a sensitivity analysis, a validated algorithm was used to determine receipt of 
ultrasounds performed with screening intent.55,82 In order to identify and distinguish these 
ultrasound tests performed for the purposes of HCC screening, the algorithm developed by 
Richardson and colleagues was applied. It is critical to note that Richardson and colleagues also 
developed and validated an algorithm to determine whether AFP tests were performed for the 
purposes of HCC screening, however as previously discussed, prior studies in literature have 
suggested that AFP decision alone lacks sensitivity and specificity for effective HCC screening 
and for diagnosis.31,63–65 Therefore, only the validated algorithm for abdominal ultrasound 
examination for HCC screening was applied in this study. 
The algorithm applied in this study was a rigorously tested logistic regression model 
developed using data from the Veterans Affairs (VA) HCV Clinical Case Registry (CCR), which 
integrated potential clinical and biological factors that may influence intent to screen for HCC.82 
The authors of the study internally validated the algorithm using direct multiple imputations, 
which was conducted by Monte Carlo-based estimates of the joint distribution of true and 
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predicted tests and then externally validated the algorithm by applying the classification 
algorithm in two other Veterans Affairs (VA) cohorts.82 Although this screening intent algorithm 
was developed using Veterans Affairs (VA) data, the screening intent algorithm has been applied 
successfully to previous HCC studies, including a study that formerly assessed HCC screening 
utilization using SEER-Medicare data.55,83 
In order to determine abdominal ultrasound tests for the purposes of HCC screening in 
this sample, the log odds of screening for HCC was obtained. This value was then calculated into 
odds and into the predicted probability of screening for each claim for an abdominal ultrasound 
test.55,82 The authors considered a number of potential predictors to model screening status, but 
chose the following predictors for the final algorithm: 1) abdominal pain, 2) ascites, 3) drug 
dependence, 4) HIV, and 5) AFP test in the last 90 days to model screening status for ultrasound 
tests based on previous univariate chi-square tests and p-values.82 Medicare claims ICD-9 codes 
were used to identify claims for abdominal pain (789.00, 789.01, 789.02, 789.03, 789.04, 789.05, 
789.06, 789.07, 789.09), ascites (789.51, 789.59), drug dependence (304.60, 304.61, 304.62, 
304.63, 304.70, 304.71, 304.72, 304.73, 304.80, 304.81, 304.82, 304.83, 304.90, 304.91, 304.92, 
304.93) and HIV (042, 795.71, V08, V65.44, 079.53). AFP test in the last 90 days was identified 
using the current procedural terminology (CPT) code, 82105 as utilized by Richardson and 
colleagues.82 The algorithm equation adapted from Richardson and colleagues is as follows, 𝐿𝑜𝑔 𝑜𝑑𝑑𝑠 𝑜𝑓 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔 𝑓𝑜𝑟 𝐻𝐶𝐶= −0.9015+−0.3943 ∗ 𝑎𝑏𝑑𝑜𝑚𝑖𝑛𝑎𝑙 𝑝𝑎𝑖𝑛 +−0.7932 ∗ 𝑎𝑠𝑐𝑖𝑡𝑒𝑠+−0.4394 ∗ 𝑑𝑟𝑢𝑔 𝑑𝑒𝑝𝑒𝑛𝑑𝑒𝑛𝑐𝑒 +−1.0723 ∗ 𝐻𝐼𝑉 + 0.8223∗ (𝐴𝐹𝑃 𝑡𝑒𝑠𝑡 𝑖𝑛 𝑡ℎ𝑒 𝑙𝑎𝑠𝑡 90 𝑑𝑎𝑦𝑠) 
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where AFP test in the last 90 days was a positive predictor of HCC screening and other variables 
were negative predictors of HCC screening.82 These predictors are shown below in Figure 5.  
 
Figure 6. Variable predictors for HCC screening intent for abdominal ultrasound tests 
 
This diagram illustrates the algorithm equation adapted from Richardson and colleagues, where variable 
predictors for HCC screening intent for abdominal are shown in the left figures. 
 
This formula was applied to every abdominal screening claim. We used a cutoff threshold 
of p=0.38 to determine whether the ultrasound test was done for the purposes of HCC 
screening.55 If the predicted probability of screening was equal to or higher than 0.38 (p>=0.38), 
which is the point of the maximum agreement threshold with the true screening test done, we 
then imputed the screening variable with a constructed binomial variable according to the 
predicted probability of screening from the logistic regression model.55,82,84,85 The authors that 
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developed the validated algorithm found this dichotomization at the 0.38 threshold showed 
higher agreement with true screening in cirrhosis patients.82 The sensitivity was 21.2% and the 
positive predictive value (PPV) was 33.3% for this algorithm.82 This algorithm intent was then 
applied to all screening dependent variables as a sensitivity analysis. 
2.2.5 Construction of Milan Criteria Variable 
Given many studies in literature have illustrated improved prognosis for patients using 
Milan Criteria compared to other tumor staging criteria in HCC, the Milan Criteria variable was 
constructed using the criteria of a single tumor <5cm or 2 to 3 tumors all <3cm with no evidence 
of extrahepatic involvement or metastasis to determine the proportion of patients diagnosed 
within Milan Criteria in this sample.26,91,98–101 
Variables indicating the number of tumors, size of each tumor and whether there was any 
extra-hepatic involvement or metastasis were available from SEER Patient Entitlement and 
Diagnosis Summary File (PEDSF file) data.101,102 
The variable titled Sequence number, “seq1-seq10” was used to indicate the number of 
tumors in a patient. The Sequence number in the SEER Patient Entitlement and Diagnosis 
Summary File (PEDSF file) reports and describes all malignant, in situ, benign and borderline 
primary tumors that occur over the lifetime of a patient. Benign tumors were determined as 
having no tumors.  
To determine tumor size, the variable titled EOD – Tumor Size “e10sz1-e10sz10” holds 
information on tumor size and pertains to cancer cases diagnosed from 1988 to 2003, and 
therefore was used for patients diagnosed with HCC in 2003 in this sample. Similarly, the 
variable titled CS Tumor Size “cstum1-cstum10” pertains to cancer cases diagnosed from 2004 
to the most present data year, 2013. Thus, this variable was used for patients who were 
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diagnosed with HCC from 2004 to 2013 in this sample. Tumor size was originally coded in 
millimeters and then converted to centimeters.  
To determine extra-hepatic involvement or metastasis, the variable titled EOD – 
Extension “e10ex1-e10ex10” holds information on the extension of the tumor either by adjacent 
extension or distant metastases size and pertains to cancer cases diagnosed from 1988 to 2003.103 
Thus, this variable was used for patients diagnosed with HCC in 2003 in this sample. Similarly, 
the variable titled CS – Extension “csex1-csex10” pertains to cancer cases diagnosed from 2004 
to the most present data year, 2013. Thus, this variable was used for patients who were 
diagnosed with HCC from 2004 to 2013 in this sample. Details on extra-hepatic involvement or 
metastasis codes specific to the liver were found in the SEER Extent of Disease 1998 Codes and 
Coding Instructions.104 
Figure 7 below illustrates how the Milan Criteria variable was constructed using existing 
variables in the SEER data. 
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Figure 7. Flow diagram for construction of Milan Criteria variable using SEER-Medicare data 
 
This figure illustrates a flow diagram describing the construction of the Milan Criteria variable using 
SEER-Medicare data for patients diagnosed with HCC from the years of 2003 to 2013.  
 
2.2.6 Construction of Cirrhosis Duration Variable 
If applicable to the patient, the first diagnosis of cirrhosis was identified using the first 
claim date that was billed for any of diagnosis for decompensated cirrhosis using the “from date” 
found in Medicare claims (MEDPAR, NCH, Outpatient files). Patients were then categorized 
into 3 cirrhosis duration groups: 
 
1) No diagnosis of cirrhosis before HCC diagnosis 
2) First cirrhosis diagnosis identified within 3-year screening period prior to HCC 
diagnosis 
3) First cirrhosis diagnosis identified before 3-year screening period 
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Patients who had their first cirrhosis diagnosis before the 3-year screening period were 
identified as patients with known cirrhosis. These details were discussed previously in the study 
population section. Patients who had their first cirrhosis diagnosis within the 3-year screening 
period prior to HCC diagnosis were grouped into the second category. The 3-year screening 
period was chosen based off of a previously similar study using SEER-Medicare data to 
characterize rates of HCC screening from 1994 to 2002. The goal of this study was to assess and 
compare HCC screening rates in recent years with previous years. Therefore the 3-year screening 
period was similarly selected. Figure 8 below visually describes how patients were categorized 
into their respective cirrhosis duration groups. 
 
Figure 8. Timeline of cirrhosis diagnosis identification 
 
This figure depicts the timeline used to identify patients with a cirrhosis diagnosis prior to their HCC 
diagnosis in order to categorize patients into appropriate cirrhosis duration groups. 
 
2.2.7 Patient Characteristics 
The main sample consisted of patients who had a code for HCC diagnosis (International 
Classification of Disease-Oncology 8170) in one of the Histology ICD-O-2 variables, “hist2_1-
hist2_10” from the SEER Patient Entitlement and Diagnosis Summary File (PEDSF file). If there 
were multiple records, we used the first diagnosis record and variables with multiple fields 
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corresponded to the number of this record. If patients had information on their diagnosis year, 
but did not have information on their diagnosis month, then the diagnosis month for that patient 
was imputed to the median month, June. Patients were dropped from the sample if any of the 
patient characteristics discussed below were missing and could not be imputed using a similarly 
available variable.  
Other variables obtained from the SEER Patient Entitlement and Diagnosis Summary 
File (PEDSF file) include age at HCC diagnosis, gender, race/ethnicity, metropolitan area (based 
on Rural/Urban Continuum Codes (RUCC) coded by SEER) of residence, Census poverty 
indicator of patient's residence (proxy for socioeconomic status), and year of HCC 
diagnosis.101,102 As previously mentioned, variables including age at HCC diagnosis and year of 
HCC diagnosis corresponded to the Histology ICD-O-2 variable “hist2_1-hist2_10” coded for 
HCC diagnosis (International Classification of Disease-Oncology 8170). Age at HCC diagnosis 
was treated as a continuous variable in years while the year of diagnosis was used as a 
categorical variable, as originally available and coded in the SEER Patient Entitlement and 
Diagnosis Summary File (PEDSF file). Census poverty indicator was determined using the 
variable “census_pov_ind” and this was a categorical variable.  
Metropolitan area of residence was determined using the “urbrur” variable in the SEER 
Patient Entitlement and Diagnosis Summary File (PEDSF file). The variable was dichotomized 
and patients who lived in Big Metro, Metro and Urban areas were denoted as living in a 
metropolitan area of residence. Likewise, patients who lived in Less Urban and Rural areas were 
denoted as living in a non-metropolitan area of residence. This stratification is shown in further 
detail below. Categories were based on 2013 Rural/Urban Continuum Codes (RUCC).103,105  
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Metropolitan areas: 
1) Big Metro=Counties in metro areas of 1 million population or more 
2) Metro=Counties in metro areas of 250,000 to 1 million population, Counties 
in metro areas of fewer than 250,000 population 
3) Urban=Urban population of 20,000 or more, adjacent to a metro area, Urban 
population of 20,000 or more, not adjacent to a metro area   
Non-metropolitan areas: 
1) Less Urban= Urban population of 2,500 to 19,999, adjacent to a metro area, 
Urban population of 2,500 to 19,999, not adjacent to a metro area 
2) Rural= Completely rural or less than 2,500 urban population, adjacent to a 
metro area, Completely rural or less than 2,500 urban population, not adjacent 
to a metro area 
 
The race/ethnicity variable was recoded as one variable using the “race” and “origin” 
variables in the SEER Patient Entitlement and Diagnosis Summary File (PEDSF file) based off 
recommendations from the U.S. Census Bureau.106 The U.S. Census Bureau considers race and 
ethnicity to be two separate distinct concepts and ethnicity determines whether a person is of 
Hispanic origin or not.106 Race and ethnicity are commonly combined in research to become 
categorical variables rather than separate categorical and binary variables to avoid 
confounding.107 If patients were classified as Mexican, Puerto Rican, Cuban, South or Central 
American, or Other Specific Spanish/Hispanic Origin, then these patients were categorized as 
Hispanic. If patients were noted as Non-Spanish/Non-Hispanic in the “origin” variable, then race 
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was used. These combinations resulted in a categorical variable with 5 groups for race/ethnicity 
in this study: 
 
1) White non-Hispanic 
2) Black non-Hispanic 
3) Hispanic 
4) Asian non-Hispanic 
5) Other race non-Hispanic 
The National Cancer Institute (NCI) Comorbidity Index to measure non-cancer 
comorbidities in the sample was used. The National Cancer Institute (NCI) Comorbidity Index 
was developed from a cohort of cancer patients and excludes solid tumors, leukemias, and 
lymphomas as comorbid conditions.108,109 The codes used to define each of the 16 conditions in 
the NCI Comorbidity Index, as well as the weights associated with each condition were provided 
by the National Cancer Institute (NCI).108 Diagnosis and procedure codes to calculate this index 
were identified from Medicare claims 1 year prior to HCC diagnosis.108,110 Patients were then 
grouped into categories as suggested by Murray and colleagues.111 
Prior to HCC diagnosis, liver disease etiology from Medicare claims ICD-9 codes were 
also identified since these are the most important risk factors for HCC. A categorical variable 
was subsequently constructed and encompassed 6 different groups: 
 
1) No liver correlated condition 
2) Hepatitis B virus (HBV) 
3) Hepatitis C virus (HCV) 
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4) Alcoholic fatty liver or alcoholic cirrhosis 
5) Other liver disease 
6) More than one liver correlated condition 
  
Patients diagnosed with hepatitis B virus (HBV) was identified using ICD-9 codes 
(70.20, 70.21, 70.22, 70.23, 70.30, 70.31, 70.32, 70.33, V02.61).112 Patients diagnosed with 
hepatitis C virus (HCV) was identified using ICD-9 codes (70.41, 70.44, 70.51, 70.54, 70.70, 
70.71, V02.62).112 Patients diagnosed with alcoholic fatty liver (571.0) and alcoholic cirrhosis 
(571.2) was identified using ICD-9 codes. ICD-9 codes used to identify patients with other liver 
disease included hemochromatosis (275.01, 275.02, 275.03), as well as acute alcoholic hepatitis, 
alcohol liver damage, biliary cirrhosis, chronic liver disease (571.1, 571.3, 571.6, 571.8).112 
Patients with hemochromatosis were grouped into the other liver disease category due to small 
sample size. Patients who had a diagnosis for hepatitis B virus (HBV), hepatitis C virus (HCV), 
alcoholic fatty liver and alcoholic cirrhosis, and other liver disease were grouped into the more 
than one liver correlated condition category.  
To determine characteristics on liver dysfunction, Medicare claims information billed for 
ascites (ICD-9 codes 789.51, 789.59) or hepatic encephalopathy (ICD-9 codes 572.2) at least 6 
months prior to HCC diagnosis was also collected.112 Pharmacy claims information billed for 
spironolactone or furosemide to determine whether a patient had ascites, and pharmacy claims 
information billed for lactulose and rifaximin to determine whether a patient had hepatic 
encephalopathy from the Medicare Part D Data file was collected. Medications were identified 
using the generic drug name “GNN” variable. 
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2.3 Results  
2.3.1 Patient Characteristics 
Between January 2003 and December 2013, 13,714 patients were diagnosed with HCC in 
the SEER Patient Entitlement and Diagnosis Summary File (PEDSF file). The number of 
patients diagnosed with HCC increased over time, from 868 patients in 2003 to 1,531 patients in 
2013. The mean age of patients was 73 years, and approximately 67% were men. The population 
was predominantly white (62%), followed by Hispanics (13%), Blacks (10%), and Asians (9%) 
and Other Race (6%). A majority of patients in the sample resided in metropolitan areas and 31% 
of the population were living 10% to <20% below the poverty line.  
Approximately 42% of HCC patients did not have any listed etiology of liver disease. 
The most common etiology of liver disease was hepatitis B virus (HBV) infection (21.3%), 
followed by other liver disease (7.9%), alcoholic fatty liver or alcoholic cirrhosis (4.9%), and 
hepatitis C virus (HCV) infection (2.8%). Approximately 21.0% of HCC patients had more than 
one liver correlated condition. Few patients had evidence of hepatic decompensation with 12% 
having ascites and 10% hepatic encephalopathy prior to HCC diagnosis. 
There were 2,972 patients in the subset sample with known cirrhosis during this same 
time period (HCC diagnosis 2003 to 2013). Approximately 22% of patients were diagnosed with 
cirrhosis prior to the study period and 21% were diagnosed with cirrhosis during the study 
period; however, more than half (57%) of patients had unrecognized cirrhosis or were non-
cirrhotic at time of HCC presentation. Of HCC patients in this subsample, roughly half (51.4%) 
had more than one liver correlated condition, with only 14.5% not having any etiology of liver 
disease prior to HCC diagnosis. About 12.0% had alcoholic fatty liver or alcoholic cirrhosis, 
followed by 11.3% of patients who had a diagnosis of other liver disease. Nearly 7.2% of 
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patients had hepatitis B virus (HBV) infection and 3.6% had hepatitis C virus (HCV) infection. 
Almost a third of patients had evidence of hepatic decompensation, with 28.5% having ascites 
and 29.6% having hepatic encephalopathy prior to HCC diagnosis. 
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Table 1. Baseline HCC patient characteristics (n=13,714) 
 Overall (%)	 Consistent 
screening* 
(%)	
Inconsistent 
screening** 
(%)	
No 
screening 
(%)	
P-value	
Mean age at HCC 
diagnosis (s.d.) 	
73.0 (9.7)	 69.8 (9.8)	 71.7 (9.9)	 74.5 (9.2)	 <0.001	
Gender	 <0.001	
Male	 9,184 (67.0)	 583 (62.2)	 3,786 (65.6) 4,815 (68.7)  
Female	 4,530 (33.1)	 354 (37.8) 1,982 (34.4) 2,194 (31.3)  
Race/ethnicity	 <0.001	
White	 8,450 (61.6)	 436 (46.5) 3,390 (58.8)  4,624 
(66.0) 
 
Black	 1,420 (10.4)	 83 (8.9) 624 (10.8) 713 (10.2)  
Hispanic	 1,805 (13.2)	 168 (17.9) 864 (15.0) 773 (11.0)  
Asian	 1,276 (9.3)	 177 (19.0) 584 (10.1) 515 (7.4)  
Other race	 763 (5.6)	 73 (7.8) 306 (5.3) 384 (5.5)  
Metropolitan area	 0.001	
Metropolitan	 12,663 
(92.3)	
884 (94.3) 5,360 (92.9) 6,419 (91.6)  
Non-metropolitan	 1,051 (7.7)	 53 (5.7) 408 (7.1) 590 (8.4)  
Census poverty indicator	 0.002	
0%-<5% poverty	 2,669 (19.5)	 168 (17.9) 1,095 (19.0) 1,406 (20.1)  
5% to <10% 
poverty	
3,279 (23.9)	 204 (21.8) 1,392 (24.1) 1,683 (24.0)  
10% to <20% 
poverty	
4,294 (31.3)	 315 (33.6) 1,739 (30.2) 2,240 (32.0)  
20% to 100% 
poverty	
3,472 (25.3)	 250 (26.7) 1,542 (26.7) 1,680 (24.0)  
Year of HCC diagnosis	 <0.001	
2003	 868 (6.3)	 47 (5.0) 358 (6.2) 463 (6.6)  
2004	 909 (6.6)	 50 (5.3) 367 (6.4) 492 (7.0)  
2005	 977 (7.1)	 47 (5.0) 435 (7.5) 495 (7.1)  
2006	 1,072 (7.8)	 62 (6.6) 452 (7.8) 558 (8.0)  
2007	 1,191 (8.7)	 80 (8.5) 504 (8.7) 607 (8.7)  
2008	 1,334 (9.7)	 66 (7.0) 562 (9.7) 706 (10.1)  
2009	 1,384 (10.1)	 71 (7.6) 607 (10.5) 706 (10.1)  
2010	 1,402 (10.2)	 113 (12.1) 578 (10.0) 711 (10.1)  
2011	 1,433 (10.5)	 107 (11.4) 612 (10.6) 714 (10.2)  
2012	 1,613 (11.8)	 122 (13.0) 690 (12.0) 801 (11.4)  
2013	 1,531 (11.2)	 172 (18.4) 603 (10.5) 756 (10.8)  
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Table 1. Continued 
 Overall (%)	 Consistent 
screening* 
(%)	
Inconsistent 
screening** 
(%)	
No 
screening 
(%)	
P-value	
Cirrhosis duration	 <0.001	
No diagnosis of 
cirrhosis	
7,876 (57.4) 117 (12.5) 2,368 (41.1) 5,391 (76.9)  
Cirrhosis diagnosis 
within 3 years of 
HCC diagnosis	
2,866 (20.9) 270 (28.8) 1,820 (31.6) 776 (11.1)  
Cirrhosis before 3 
year screening 
period	
2,972 (21.7)	 550 (58.7) 1,580 (27.4) 842 (12.0)  
Milan criteria	 <0.001	
Yes	 4,811 (35.1)	 596 (63.6) 2,443 (42.4) 1,772 (25.3)  
No	 8,903 (64.9)	 341 (36.4) 3,325 (57.7) 5,237 (74.7)  
HCC etiology	 <0.001	
No liver correlated 
conditions	
5,778 (42.1) 142 (15.2) 1,902 (33.0) 3,734 (53.3)  
HBV	 2,915 (21.3) 86 (9.2) 1,010 (17.5) 1,819 (25.6)  
HCV	 390 (2.8) 35 (3.7) 188 (3.3) 167 (2.4)  
Alcoholic fatty 
liver or alcoholic 
cirrhosis	
669 (4.9) 57 (6.1) 362 (6.3) 250 (3.6)  
Other liver disease	 1,077 (7.9) 133 (14.2) 629 (10.9) 315 (4.5)  
More than one 
liver correlated 
condition	
2,885 (21.0) 484 (51.7) 1,677 (29.1) 724 (10.3)  
Ascites	 <0.001	
Yes	 1,609 (11.7) 270 (28.8) 1,011 (17.5) 328 (4.7)  
No	 12,105 
(88.3) 
667 (71.2) 4,757 (82.5) 6,681 (95.3)  
Hepatic encephalopathy	 <0.001	
Yes	 1,318 (9.6) 287 (30.6) 796 (13.8) 235 (3.4)  
No	 12,396 
(90.4) 
650 (69.4) 4,972 (86.2) 6,774 (96.7)  
NCI comorbidity index score	 <0.001	
None (0)	 954 (7.0) 5 (0.5) 186 (3.2) 763 (10.9)  
Low (1-2)	 3,160 (23.0) 85 (9.1) 975 (16.9) 2,100 (30.0)  
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Table 1. Continued 
 Overall (%)	 Consistent 
screening* 
(%)	
Inconsistent 
screening** 
(%)	
No 
screening 
(%)	
P-value	
Moderate (3-4)	 3,555 (25.9)	 188 (20.1) 1,476 (25.6) 1,891 (27.0)  
High (5+)	 6,045 (44.1) 659 (70.3) 3,131 (54.3) 2,255 (32.2)  
*Having ≥1 abdominal ultrasound per calendar year 
**Having ≥1 abdominal ultrasound during the study period but less than annually 
This table illustrates a comparison of patient characteristics among all patients diagnosed with HCC 
from the years of 2003 to 2013 who received consistent, inconsistent and no screening in the 3 years prior 
to their HCC diagnosis. 
 
2.3.2 HCC Screening Receipt 
Most (51.1%) patients did not receive any screening in the 3 years prior to HCC 
diagnosis, while 42.1% had inconsistent screening, and only 6.8% underwent consistent 
screening (Table 2). After accounting for screening intent, only 16.4% of patients underwent 
inconsistent screening, and 2.0% consistent screening and 81.6% did not receive any screening. 
Screening receipt was higher in the subset of patients with known cirrhosis, with 53.2% and 
18.5% receiving inconsistent and consistent screening, respectively. Roughly 28.3% of known 
cirrhosis patients did not receive any HCC screening. 
 
Table 2. Frequency of HCC screening receipt (Diagnosis years 2003 to 2013) 
 Primary sample (n=13,714)	 Cirrhosis sample (n=2,972)	
 No intent	 Screening intent	 No intent	 Screening intent	
Consistent 
screening*	
937 (6.8%)	 278 (2.0%)	 550 (18.5%)	 199 (6.7%)	
Inconsistent 
screening**	
5,770 (42.1%)	 2,244 (16.4%)	 1,580 (53.2%)	 1,068 (35.9%) 
No screening	 7,010 (51.1%)	 11,192 (81.6%)	 842 (28.3%) 1,705 (57.4%)	
*Having ≥1 abdominal ultrasound per calendar year 
**Having ≥1 abdominal ultrasound during the study period but less than annually 
This table illustrates the frequency of HCC screening receipt among all and known cirrhosis patients 
diagnosed with HCC from the years of 2003 to 2013 using the three mutually exclusive categories. 
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The mean PUTD was 13.4% ± 20.7% for all patients and 27.6% ± 26.8% for those with 
known cirrhosis. Excluding those without any screening, the mean PUTD was still low at 27.4% 
± 22.1%. After accounting for screening intent, the mean PUTD was only 5.0% ± 13.5% for all 
patients and 13.8% ± 20.9% for those with known cirrhosis. 
 
Figure 9. Proportion of time up-to-date (PUTD) HCC screening  
 
This figure illustrates the distribution of proportion of time up-to-date (PUTD) screening receipt among 
all patients diagnosed with HCC from the years of 2003 to 2013. Panel A illustrates the distribution of 
data for the primary sample, and Panel B illustrates a sensitivity analysis with screening intent applied to 
the primary sample. 
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Figure 10. Proportion of time up-to-date (PUTD) HCC screening (Known Cirrhosis sample) 
 
This figure illustrates the distribution of proportion of time up-to-date (PUTD) screening receipt among 
known cirrhosis patients diagnosed with HCC from the years of 2003 to 2013. Panel A illustrates the 
distribution of data for patients with known cirrhosis, and Panel B illustrates a sensitivity analysis with 
screening intent applied to this sample. 
 
The proportion of patients receiving consistent screening steadily increased over time 
from 5.4% for patients diagnosed between 2003 – 2006 to 6.2% between 2007-2010 and 8.8% 
between 2011 – 2013. Likewise, the number of patients with no screening slightly decreased 
from 52.5% during 2003 - 2006 to 49.6% during 2011 - 2013. Consistent screening increased 
from 16.4% to 21.2% over this time period in the subset of patients with known cirrhosis. 
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Table 3. Percent (%) change in HCC screening receipt over time (Diagnosis years 2003 to 2013) 
 Primary sample (n=13,714) Cirrhosis sample (n=2,972) 
 No intent Screening intent No intent Screening intent 
 2003 
to 
2006 
2007 
to 
2010 
2011 
to 
2013 
2003 
to 
2006 
2007 
to 
2010 
2011 
to 
2013 
2003 
to 
2006 
2007 
to 
2010 
2011 
to 
2013 
2003 
to 
2006 
2007 
to 
2010 
2011 
to 
2013 
Consistent 
screening* 
5.4 6.2 8.8 1.4 2.0 2.6 16.4 16.5 21.2 6.1 6.1 7.5 
Inconsistent 
screening** 
42.1 42.4 41.6 13.6 16.7 18.3 53.9 54.7 51.4 31.6 36.2 37.4 
No 
screening 
52.5 51.4 49.6 85.0 81.3 79.1 29.6 28.8 27.4 62.3 57.6 55.1 
*Having ≥1 abdominal ultrasound per calendar year 
**Having ≥1 abdominal ultrasound during the study period but less than annually 
This table depicts the percent change in screening among patients diagnosed with HCC from the years of 
2003 to 2013 during the 3 years prior to their HCC diagnosis. 
 
2.4 Discussion 
More than half of patients had unrecognized cirrhosis or were non-cirrhotic at the time of 
HCC presentation. This may be due to asymptomatic presentation of chronic liver disease and 
the prolonged progression of fibrosis and its associated complications.36,65 There are continued 
limitations to early diagnosis of liver cirrhosis using imaging.36 Ultrasound imaging can provide 
early detection of morphological changes of the liver, but these changes unfortunately already 
signify advanced cirrhosis.36 Historically, fibrosis was assessed via biopsy, which is 
unfortunately invasive and therefore not often used in clinical practice now.36 Despite the 
availability of non-invasive markers of fibrosis, this method of biopsy is still used in some 
patients.36 Thus, diagnostic methods for advanced liver cirrhosis are accurate, but consequently 
early diagnosis remains difficult.36 To address this issue, Martin and colleagues recommend a 
combination of non-invasive serum and radiologic non-invasive markers to potentially identify 
patients with cirrhosis.65 Due to the high number of patients with unrecognized cirrhosis prior to 
HCC diagnosis in this study, findings suggest further research in targeted interventions to reduce 
the rate of unrecognized cirrhosis so appropriate HCC screening can be recommended to patients 
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at risk. It is critical to note that studies in literature have also suggested lack of liver disease 
etiology and difficulty in recognizing other liver diseases such as nonalcoholic fatty liver disease 
(NASH) in many patients, which is logical given HCV among patients at risk are under tested. 
Two different measures: 1) mutually exclusive categories (consistent vs. inconsistent vs. 
no screening) and 2) PUTD with screening were used to define and characterize the rate for HCC 
screening receipt in this study. Results for HCC screening receipt using both measures were 
similar, however the proportion of time up-to-date with screening (PUTD) measure allowed for 
the identification of HCC patients who received timely, consistent screening prior to diagnosis. 
Screenings rates from this study demonstrate not only is HCC screening underutilized in clinical 
practice, up-to-date adherence to HCC screening is also low (13.8%), demonstrating another 
major concern in addition to underutilization. This aspect of adherence to HCC screening is very 
important in order to identify patients who receive gaps in screening care, and could not have 
been identified using the categorical measure. Almost half (42.1%) of all HCC patients had 
received inconsistent screening (categorical) in this study, however the PUTD measure would 
indicate that patients actually receiving inconsistent screening is higher. 
This is the first study to report a (PUTD) measure among a large population based 
sample. These findings provide a significant contribution in helping to better understand patterns 
of HCC screening adherence and to characterize patterns of underuse in screening for HCC. 
Continued intervention to improve identification of at risk patients is highly necessary, as well as 
identification of other effects that may influence adherence to HCC screening. 
Since two pioneering international guidelines were announced in 2001 by The European 
Association for the Study of the Liver (EASL) and in 2005 by The American Association for the 
Study of Liver Diseases (AASLD) regarding HCC management, consistent and PUTD HCC 
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screening rates was expected to greatly improve given this study pertained to practices 
surrounding HCC diagnosis from 2003 to 2013. Screening rates in HCC were still substantively 
lower than those currently seen for other cancers, possibly due to under recognition of patients at 
risk for HCC, as well as lack of education in primary care physicians regarding the significance 
for HCC screening.12 Rates for colon, breast, and cervical cancer screening were more than 
roughly 60% for most of the United States, while rates for HCC screening continue to be much 
lower in comparison.29,113,114 
Patients with known cirrhosis have higher rates of consistent screening and inconsistent 
screening when compared to the overall sample of patients. Even after accounting for screening 
intent, this remained true. However, consistent HCC screening receipt for patients with known 
cirrhosis was also still lower than expected. Using a less stringent definition of consistent 
screening, Davila and colleagues found only 17% of patients with a diagnosis of cirrhosis 
received consistent screening, and 38% received inconsistent screening during practices from 
1994 to 2002 from the SEER-Medicare data.55 In addition, from 1998 to 2005 the annual HCC 
screening rate was only 12% in 13,002 HCV-infected veterans within the 3 years after being 
diagnosed with cirrhosis.67,115 The mean PUTD for patients with known cirrhosis was only 
slightly better during these same years. Given cirrhosis is a well-known risk factor for HCC, 
higher rates of consistent screening were anticipated in this study.32  
A study in 2013 by Singal et al. reported a screening failure of 70% in patients with 
tumors beyond Milan Criteria, despite performing US and AFP test in a Hepatitis C Antiviral 
Long-Term Treatment against Cirrhosis Trial (HALT-C).67,116 In this study, HCC screening rates 
were found to have marginally increased over time, however less than half of at-risk patients in 
this a population based cohort of patients in the United States underwent any HCC screening 
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over the 3-year period prior to HCC diagnosis. The results of this study were consistent with 
other findings in literature given many studies have reported underutilization of HCC screening.  
Results from sensitivity analysis further confirm low utilization of HCC screening 
receipt. After applying screening intent, consistent HCC screening receipt decreased 4.8%, down 
to 2.0% in all patients. For patients with known cirrhosis, consistent HCC screening receipt 
decreased 11.8%, down to only 6.7%. 
2.4.1 Limitations 
This study is unique and broadens the literature by informing providers, researchers and 
policymakers regarding improved alternative measurements for HCC screening, as well as tumor 
staging concepts for patients who were diagnosed with HCC in a large population based, 
administrative data in the United States. Despite these strengths, the analysis has several 
limitations. Despite applying the intent algorithm to the data, this method of measurement is still 
limited since it is uncertain if screening was administered solely for HCC screening purposes 
without a retrospective medical chart review. It is difficult to discern whether the provider or 
patient sought HCC screening, or whether there were other factors influencing the choice to 
screen. Liver disease and cirrhosis also continue to be under recognized in clinical practice, 
translating to lack of information in patient medical charts and subsequent deficiency in coding 
and information in large population datasets.52 Further, there may be some patients in whom 
screening may not be indicated (patients with comorbidities or severe liver dysfunction).116,117 
Further, the results of this study cannot be generalizable to a wider population and may 
only be representative of the Medicare Fee-For-Service (FFS) population.118 Medicare data does 
not encompass claims for care provided in other settings, such as the Veterans Administration or 
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Medicare Part C (aka Medicare Advantage) plans, care for persons with Medicare as the 
secondary payer, and out of pocket expenditures for services not covered.118,119 
2.5 Conclusion 
This study is distinctive as it characterizes HCC screening using both a categorical and 
continuous variable. The constructed PUTD measure has the potential to enhance the power of 
future regression analyses, as well as provide further details in adherence and gaps surrounding 
HCC screening. HCC screening receipt was defined using two different measures: 1) mutually 
exclusive categories (consistent vs. inconsistent vs. no screening) and 2) PUTD with screening. 
Results for HCC screening receipt using both measures were similar, however it is recommended 
that the PUTD measure be used in order to further understand HCC screening utilization in 
clinical practice. 
Both screening measures suggest HCC screening is heavily underutilized in the United 
States; likely contributing to high rates of late stage diagnosis and poor survival. Findings from 
this study continue to suggest that recommendations from previous studies in literature have not 
been well integrated into clinical practice. Routine HCC screening was anticipated to have 
greatly improved during more recent years, however this was not the case even in cirrhosis 
patients. Suggestions for future studies include aiming to understand why HCC screening is still 
heavily underutilized, especially for patients who are diagnosed with cirrhosis and are at high 
risk of developing HCC. 
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3. PATIENT AND PROVIDER FACTORS ASSOCIATED WITH HCC SCREENING 
RECEIPT 
 
3.1 Introduction 
HCC screening is underutilized in clinical practice and a better understanding of factors 
influencing variations in HCC screening receipt is needed. Not all patients are equally likely to 
receive cancer screening. Factors associated with differences in receipt of screening have been 
well researched for many cancers, such as mammography and colonoscopy, but unfortunately 
have not been for HCC. The past literature investigating determinants of HCC screening, though 
less extensive, generally has found variations in screening relating to certain patient 
characteristics, including age, gender, race/ethnicity, and HCC etiology.16,27,56,120 Study results 
from Singal et al. suggest patient education and employment status could predict screening rates, 
however the association was not statistically significant.121 Another study by Singal et al. found 
lower rates of HCC screening among African Americans and underinsured patients.16 African 
Americans were also less likely to receive HCC screening compared to Whites in the national 
Veterans Affairs (VA) database, and other non-Whites had a trend toward lower screening 
rates.115 Screening underutilization could even be related to several other factors, including 
patient noncompliance.16,30,64 Unfortunately, these factors still have not been well determined.  
Moreover, provider and practice facility characteristics may also be associated with 
variations in HCC screening receipt. For example, lack of provider orders, and/or limited 
radiologic capacity (including in-practice capacity and lack of imaging facilities in rural areas) 
could create barriers to screening for patients at risk for HCC.12,23 Under recognition of liver 
disease and cirrhosis were also contributors to underuse of HCC screening in some providers.12 
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In 1998, a survey study reported that 84% of hepatologists regularly screened patients with 
cirrhosis and a meta-analysis study by Singal et al. in 2011 found that patients who received care 
from gastroenterologists/hepatologists had notably higher HCC screening rates compared to 
patients who received care from primary care physicians (52% vs. 17%, p<0.001).12,117,122 
Multiple studies have suggested that differences in HCC screening were likely linked to variation 
in provider knowledge and attitudes rather than to patient-level factors such as socioeconomic 
status.12,52,64,123 Still, relatively little is known regarding provider characteristics beyond 
knowledge and attitudes in regard to predictors that may mediate screening receipt.12,22,23,30,121  
HCC screening is highly dependent upon multiple levels of contextual influence, 
including factors at the patient-level, provider-level, system-level, local community environment, 
and state and national policy.28,49 The theory of complex adaptive systems suggests that 
interactions between people and levels travel in multiple directions and individuals and layers 
within the system are constantly adapting. In addition, influences between contextual levels may 
not be completely hierarchial.49 By building on the QCCC conceptual framework and the 
Andersen model, factors that may influence HCC screening receipt were identified in this study 
in order to understand variations in HCC care delivery.49,58–60  
 Possible influences of patient and provider characteristics on HCC screening receipt 
remain poorly understood. A better understanding of these factors can guide intervention targets 
to improve future HCC screening receipt. The second study of this dissertation examined patient 
and provider characteristics that may influence HCC screening receipt in a racially/ethnic diverse 
population in a large population based, administrative data in the United States from 2003 to 
2013.  
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Background 
Most cancer care in the beginning involves internal medicine or family practice 
providers, whereas care surrounding the diagnosis and detection involve subspecialty 
providers.50 However, at risk patients typically can receive an abdominal ultrasound (HCC 
screening) from any number of specialty provider for many reasons.124,125 The initial diagnosis of 
HCC may involve multiple steps from the point of detection of potential HCC by an internal 
medicine or family practice provider or gastroenterology provider if the patient was referred to 
care from the internal medicine or family practice provider. Care for HCC is not a standardized 
protocol in clinical practice and abdominal ultrasounds can be ordered for a wide array of 
reasons.125 A referral to a vascular/interventional radiology provider for further imaging, or to a 
general surgery specialist in some rare instances for a biopsy could subsequently occur after the 
abdominal ultrasound. Every type of care involves multiple providers and every provider visit is 
a step in screening or symptomatic detection.50 Thus, the detection of cancer can involve many 
providers.51,124,125  
In addition, provider characteristics such as practice arrangement, years of experience 
and training location may impact HCC screening receipt. Practice arrangement can affect 
capacity, resources as well as culture and beliefs to screen.  Group practices typically have the 
advantage of increased productivity, the team based approach and economies of scale (group 
practices lower costs due to shared resources).126,127 However, solo practices may benefit from 
autonomy and preference of providing care without interference of a large organization. 126,127 
Hospital-based practices typically require management principals and have a system-approach to 
health care delivery, which is often adopted from engineering systems.128 Medical school 
affiliated practices offer a unique learning environment with increased accountability and a 
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shared repertoire among physicians, which may positively impact a provider’s knowledge and 
awareness regarding HCC screening. Further, limited radiologic capacity (including in-practice 
capacity and lack of imaging facilities in rural areas) could create barriers to screening for 
patients at risk for HCC.12,23 These differences in various practice arrangements may contribute 
to the differing of quality of care for cancer patients and consequently discrepancies in outcomes. 
Studies surrounding provider age and the impact of delivering healthcare suggest age and 
experience at the time of a patient encounter may or may not affect use of medical 
knowledge.129,130 Declining clinical performance may be associated with greater age.129,130 
Further, given medicine is a rapidly evolving field with many changes in training approach and 
guidelines, there may be a difference in association of HCC screening between younger and 
older age providers.129 
There are various differences in medical education and clinical management, in addition 
to differences in healthcare systems in the United States compared to other countries.131 A study 
assessing the differences in medicine between the United States and Australia noted that in 
cancer screening, the U.S. recommended colon cancer every 5 to 10 years starting at age 50 
compared to every 2 years starting at age 50 for Australia.131 Regarding medical education, the 
U.S. requires numerous national examinations to progress into clinical years, graduate and then 
obtain a medical license while the student’s medical school administers undergraduate 
examinations in Australia.131 These are just some of many differences in U.S. training status that 
may cause a provider trained in the U.S. or a provider trained in a different country to screen for 
HCC. 
 
 
  53 
3.2 Methods 
3.2.1 Data Source 
A retrospective cohort study using the Surveillance, Epidemiology and End Results 
(SEER)-Medicare data linked to the American Medical Association (AMA) Master File was 
conducted. Linked SEER-Medicare data combines clinical, demographic and survival 
information for persons with cancer from the SEER program of cancer registries with Medicare 
claims information on covered health services from time of Medicare eligibility until death.  
The SEER program collects data on incident cancer cases from 20 cancer registries and 
these areas account for approximately 28% of the population in the United States.69,72 Medicare 
is the primary health insurer for individuals ages 65 years and older and roughly 95% of 
Medicare beneficiaries are covered by both Part A (inpatient hospitalizations) and Part B 
(outpatient visits and physician office visits/services) benefits, and in 2013 about 28% were 
covered by a Medicare Advantage plan.55 The American Medical Association (AMA) Master 
File includes current and historical data for more than 1.4 million physicians, residents and 
medical students in the United States, Puerto Rico, Virgin Islands and certain Pacific Islands. 
Data includes information about education, training and professional certification and 
credentialing.132,133 
3.2.2 Study Population 
Medicare beneficiaries, aged 65 years and older, with HCC were identified using the ICD-O 
code 8170 for HCC. Only HCC patients diagnosed from the years of 2003 to 2013 were included 
in the sample.76 Patients that were not diagnostically confirmed with HCC, were not enrolled in 
Medicare Part A and B at least 3 years prior to HCC diagnosis, and were enrolled in Medicare 
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Health Maintenance Organizations (HMOs) were excluded from the sample. HCC patients with 
missing patient and tumor characteristics also were excluded.55,71  
Patients with known cirrhosis were defined, as previously discussed in the first study 
(Figure 3).55,77 For provider analyses, patients who exclusively saw emergency medicine 
physicians or physicians with no information regarding specialty, practice arrangement, or 
medical school graduation date were excluded. If any of the above-mentioned provider 
characteristics were missing then these patients were not included in the final sample. 
3.2.3. HCC Screening Definition 
The same measure of outcome regarding HCC screening receipt was used from the first 
study of this dissertation. HCC screening receipt during the 3-year period prior to HCC diagnosis 
was defined using the proportion of time up-to-date with screening (PUTD) measure in order to 
enhance the power of this analysis, given dichotomizing or categorizing variables that can be 
continuous can reduce the correlation with the true values.78,81  
The PUTD screening measure was defined as the proportion of the 36-month study 
period in which patients had received screening, with each abdominal ultrasound providing 7 
months of screening coverage. The categorical measure defined as three mutually exclusive 
groups: 1) consistent screening 2) inconsistent screening and 3) no screening as discussed in the 
first study of this dissertation was also used as the dependent variable, but only for sensitivity 
analysis. 
For screening dependent variables, receipt of an abdominal ultrasound was identified 
using the current procedural terminology (CPT) codes 76700 and 76705 in Medicare claims files. 
75 
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3.2.4 Patient Characteristics 
Independent variables consisting of patient characteristics were included for analysis. 
Information on gender, race/ethnicity, metropolitan area, Census poverty indicator of patient's 
residence (proxy for socioeconomic status), year of HCC diagnosis, and tumor characteristics 
was collected from the SEER Patient Entitlement and Diagnosis Summary File (PEDSF file) as 
noted in the previous study.101,102 Liver disease etiology from Medicare claims ICD-9 codes was 
identified. Patients were categorized into having no liver correlated condition, hepatitis B virus 
(HBV), hepatitis C virus (HCV), alcoholic liver disease or non-alcoholic fatty liver disease, other 
liver disease, and having more than one liver correlated condition. Duration of cirrhosis was also 
determined for patients, as previously discussed in the first study of this dissertation. 
3.2.5 Provider Characteristics 
Two different provider measures were utilized as independent variables to assess the 
association of provider characteristics on HCC screening receipt. 
Types of Providers Visited 
The goal of this study was to measure exposure to HCC screening and identify which 
provider specialty was most likely to screen for HCC. For each patient, variables indicating 
whether they saw a specific category of clinic provider during the 3-year screening period were 
created. These clinic provider variables were coded as dummy or binary variables for each 
category given each patient typically sees multiple providers for cancer care. There were a total 
of 6 provider specialty categories: 
 
1) Internal medicine/ family practice 
2) Gastroenterology 
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3) Hematology/oncology 
4) Vascular/interventional radiology 
5) General surgery 
6) Other specialty 
Provider specialty was identified from the American Medical Association (AMA) Master 
File using the variable “PrimarySpecialty” codes from the AMA Physician Specialty Groups and 
Codes data dictionary to determine self-designated specialty.132–134 Provider specialty categories 
were determined in part with a licensed gastroenterologist and hepatologist, Dr. Amit Singal. 
Providers visited within 1 month prior to HCC diagnosis were excluded from the analysis.  
Alternative measures that were discussed to assess the association of provider 
characteristics and HCC screening included creating a mutually exclusive variable with six 
various categories for the most commonly seen provider or the principal provider. However, 
grouping the principal provider into mutually exclusive categories would not provide the most 
accurate depiction of which provider specialty was most likely to screen for HCC given with six 
groups the loss of information can be small.49,78,135  
Categorizing the principal provider into six categories would reduce the statistical power 
to detect the true relationship between the principal provider and screening receipt. 
Categorization may also lead to an underestimation of the extent of variation in outcome among 
groups.136 For example, a patient who may have seen a provider in general surgery 6 times 
compared to a provider in gastroenterology 5 times would have the general surgery provider as 
the principal provider. This characterization could mislead results since the goal of the study was 
to measure which provider specialties were most likely to screen for HCC and thus one provider 
specialty could be seen as very different rather than similar.136 Results from a categorical 
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variable would also illustrate the value of one result relative to the average of all six providers.136 
Thus, it is necessary to capture all visits with all providers to more accurately determine which 
provider may be more likely to screen for HCC.  
Arguably, patient exposure to various categories of providers could have been quantified 
as the percent of total visits in each provider category, however this percent measure can differ 
greatly for patients with the same number of visits to a specific provider type, but different total 
visit counts to any provider. 
Principal Provider 
In addition, the most commonly seen provider was determined during the study period in 
order to measure other provider characteristics that may be attributable to HCC screening receipt. 
The most commonly seen provider was defined as the patient’s principal provider since the goal 
of this study was to identify the provider that cared for the patient the most. The provider with 
the highest total amount of reimbursement was determined as the most commonly seen provider. 
If there was a tie in highest total amount of reimbursements or this information was not 
available, then number of visits was used.  Reimbursement amount and number of visits was 
collected from Medicare claims data using the variables claim payment amount “pmt_amt” 
which is the total amount of payment to the provider for services covered and record count 
“rec_count” for each claim respectively. This methodology was adapted from Davila and 
colleagues.55  
For this principal provider, the provider’s practice arrangement, year of graduation and 
U.S. training status was collected and assigned to each of the principal provider’s patients in the 
data.55 Provider age and gender information were also collected, however due to a large number 
of missing data, these variables were removed from the analysis.  
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Practice arrangement was categorized as solo practice, group practice, hospital-based, 
medical school affiliated, or other. Practice arrangement information was available and collected 
from the American Medical Association (AMA) Master File. The variable used was 
“PresentEmployment.” Practice arrangement may affect the capacity to provide screening and 
therefore was a variable of interest in this study (Spearman's rank correlation coefficient 
p<0.001). Year of medical school graduation (used as a proxy to determine provider age and 
experience) and U.S. training status were also obtained from the American Medical Association 
(AMA) Master File.   
3.2.6 Statistical Analysis 
A multivariate two-part regression model was used to identify patient and provider 
predictors of screening receipt, where the outcome variable was defined as PUTD. For the two-
part regression model, the first part predicts the probability of any HCC screening (PUTD > 0), 
while the second part predicts the continuous proportion amount of screening receipt after 
excluding those without any screening (the value of PUTD above zero). The dependent variable 
in the second part is logged to reduce the influence of outliers.137 Testing in a two-part model 
requires calculating the full effect, which is a combination of the effect of HCC screening in each 
of the two parts.  
To determine predictors of change in screening receipt, likelihood ratio tests were used to 
determine heteroskedasticity to check for any inconsistent variance in residuals and goodness-of-
fit on the full model for the primary sample where all explanatory variables, including provider 
characteristics were included against the reduced model. This model was obtained by omitting 
variables that were not statistically significant at p>0.05 in the full model and re-estimating the 
remaining coefficients. Akaike Information Criterion (AIC) was used to determine best fit and 
  59 
found that the reduced model for all regression analyses had the lowest AIC and therefore was 
the preferred model. Multicollinearity was also tested between pairs of coefficients to determine 
any collinearity issues using the variance inflation factor (VIF) scores. 
3.2.7 Sensitivity Analyses 
Two sensitivity analyses were conducted to determine the robustness of findings. To 
evaluate predictors of different levels of screening using the constructed mutually exclusive 
categories (consistent vs. inconsistent vs. no screening) as previously mentioned in the first study 
of this dissertation, a generalized ordered logistic model was assessed. A generalized ordered 
logistic regression model was preferred for the categorical dependent variable since the Brant 
Test of Parallel Regression Assumption was significant. The parallel regression assumption, or 
the proportional odds assumption assumes that the relationship between each pair of outcome 
groups is the same.138,139 The result of the Brant Test of Parallel Regression Assumption 
indicated that the parallel regression assumption was violated and therefore an ordered logistic 
regression model should not be used.138,139 The generalized ordered logistic regression model 
overcomes this violation by fitting partial proportional odds model, where the parallel lines 
constraint is relaxed.139 Generalized ordered logistic regression model results were reported in 
Appendix Table 7A. A multivariate tobit regression model also was used to account for the 
lower-bound limit (zero) for the outcome variable (PUTD).  
Receipt of ultrasounds performed with screening intent, as determined by a validated 
algorithm previously described in the first study of this dissertation was characterized as well. 
This validated algorithm was applied to all regression analyses in this study.55,82 
STATA 14.0 (StataCorp, College Station, TX, USA) and SAS 9.4 (SAS Institute Inc., 
Cary, NC) were used for all statistical analyses. The study protocol was approved by the 
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Institutional Review Board of Texas A&M University and the Institutional Review Board of the 
U.S. National Cancer Institute (NCI), Division of Cancer Control & Population Sciences. 
3.3 Results 
3.3.1 Physician Characteristics 
A quarter (25%) of all HCC patients visited an internal medicine/family practice 
provider, and another quarter (25%) of HCC patients visited a provider in the other specialty 
category in the 3-year screening period prior to their HCC diagnosis. Approximately 23% visited 
a vascular/interventional radiology provider, followed by roughly 14% who visited a provider in 
gastroenterology provider. The least provider specialty seen was hematology/oncology (5.3%). 
Of all HCC patients who received consistent screening, 20% visited a gastroenterology provider, 
while almost a quarter visited an internal medicine/family practice provider, a 
vascular/interventional radiology provider or a provider in the other specialty category (Table 4). 
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Table 4. Types of provider specialties visited prior to HCC diagnosis (n=13,714) 
 Overall (%) Consistent 
screening* 
(%) 
Inconsistent 
screening** 
(%) 
No 
screening 
(%) 
P-value 
Provider specialty visited  
Internal Medicine/ 
family practice 
12,689 (24.9) 921 (21.5) 5,559 (23.1) 6,209 (27.4) <0.001 
Gastroenterology 7,032 (13.8) 840 (19.6) 3,895 (16.2) 2,295 (10.1) <0.001 
Hematology/ 
Oncology 
2,699 (5.3) 278 (6.5) 1,466 (6.1) 955 (4.2) <0.001 
Vascular/ 
Interventional 
Radiology 
11,809 (23.1) 923 (21.6) 5,503 (22.8) 5,383 (23.7) <0.001 
General Surgery 4,066 (8.0) 391 (9.1) 2,106 (8.7) 1,569 (6.9) <0.001 
Other 12,757 (25.0) 924 (21.6) 5,571 (23.1) 6,262 (27.6) <0.001 
*Having ≥1 abdominal ultrasound per calendar year 
**Having ≥1 abdominal ultrasound during the study period but less than annually 
This table depicts a comparison of provider specialties seen for all patients diagnosed with HCC from the 
years of 2003 to 2013 who received consistent, inconsistent and no screening in the 3 years prior to their 
HCC diagnosis. 
 
Regarding the principal provider for each patient, nearly half of all patients saw a 
provider employed in a group practice setting (48%), with less than 10% being in a hospital or 
medical school-based setting. Most providers graduated from medical school from the years of 
1969 to 1984 (46.3%) and 1985 to 2000 (40.9%). A majority of providers (67.6%) were trained 
in the United States. Descriptive results are shown in Table 5. 
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Table 5. Baseline principal provider characteristics for HCC patients (n=13,714) 
 Overall (%) Consistent 
screening* 
(%) 
Inconsistent 
screening** 
(%) 
No 
screening 
(%) 
P-value 
Principal provider specialty <0.001 
Internal Medicine/ 
family practice 
8,016 (58.5) 503 (53.7) 3,438 (59.6) 4,075 (58.0)  
Gastroenterology 937 (6.8) 189 (20.2) 502 (8.7) 246 (3.5)  
Hematology/ 
Oncology 
412 (3.0) 10 (1.1) 120 (2.1) 282 (4.0)  
Vascular/ 
Interventional 
Radiology 
195 (1.4) 9 (1.0) 73 (1.3) 113 (1.6)  
General Surgery 431 (3.1) 47 (5.0) 202 (3.5) 182 (2.6)  
Other  3,723 (27.2) 179 (19.1) 1,433 (24.8) 2,111 (30.1)  
Practice arrangement <0.001 
Solo practice 4,707 (34.3) 347 (37.0) 2,076 (36.0) 2,284 (32.6)  
Group practice 6,588 (48.0) 400 (42.7) 2,720 (47.2) 3,468 (49.5)  
Hospital 1,000 (7.3) 76 (8.1) 394 (6.8) 530 (7.6)  
Medical school 127 (0.9) 17 (1.8) 52 (0.9) 58 (0.83)  
Other 1,292 (9.4) 97 (10.4) 526 (9.1) 669 (9.5)  
Medical school graduation year 0.058 
-1968 1,345 (9.8) 84 (9.0) 534 (9.3) 727 (10.4)  
1969-1984 6,344 (46.3) 414 (44.2) 2,654 (46.0) 3,276 (46.7)  
1985-2000 5,615 (40.9) 405 (43.2) 2,416 (41.9) 2,794 (39.9)  
2001- 410 (3.0) 34 (3.6) 164 (2.8) 212 (3.0)  
U.S. training status <0.001 
Yes 9,274 (67.6) 601 (64.1) 3,750 (65.0) 4,923 (70.2)  
No 4,140 (30.2) 319 (34.0) 1,894 (32.8) 1,927 (27.5)  
Unknown 300 (2.2) 17 (1.8) 124 (2.2) 159 (2.3)  
*Having ≥1 abdominal ultrasound per calendar year 
**Having ≥1 abdominal ultrasound during the study period but less than annually 
This table illustrates a comparison of provider characteristics for all patients diagnosed with HCC from 
the years of 2003 to 2013 who received consistent, inconsistent and no screening in the 3 years prior to 
their HCC diagnosis. 
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3.3.2 Predictors of Screening Receipt 
As reported in Table 6, the logistic regression model results indicated that receipt of any 
HCC screening was associated with younger patient age, female gender, Asian race and other 
race, a diagnosis of cirrhosis within 3 years prior to HCC diagnosis, presence of other liver 
disease, presence of more than one liver correlated condition, presence of decompensated 
cirrhosis, higher comorbidity score and having visited a gastroenterologist or 
vascular/interventional radiologist (p≤0.001).  
There was no difference in year of HCC diagnosis overall and results were not 
statistically significant (p>0.05). Results from the logistic regression model also suggest there 
were overall no differences in provider practice arrangement, since results were not statistically 
significant (p>0.05) except for principal providers in the hospital setting. Having seen a principal 
provider that was trained in the United States was also statistically significant in this model, 
however the direction was negative (p<0.05). These results suggest having seen a principal 
provider that was not trained in the United States may indicate increased receipt of any HCC 
screening. 
However, after excluding patients without any screening, the association between HCC 
screening and higher comorbidity score and having visited a vascular/interventional radiologist 
were no longer statistically significant (p>0.05). In the conditional OLS analysis, patient age, 
female gender, Asian race and other race, and having a diagnosis of cirrhosis prior to HCC 
diagnosis was associated with increased HCC screening (p<0.05). In addition, presence of HBV, 
presence of other liver disease, and presence of more than one liver correlated condition was 
associated with increased HCC screening (p<0.05). Having visited a specialty provider from the 
other category was also associated with increased HCC screening, however having visited a 
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gastroenterologist had a higher association with increased HCC screening (p<0.001). Further, 
having seen a principal provider in a group practice setting was associated with increased HCC 
screening among patients who were screened (p<0.05). Overall, there was no difference in year 
of HCC diagnosis and having seen a principal provider that was trained in the United States.  
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Table 6. Estimation results for predictors of change in HCC screening receipt using a two-part 
regression model (n=13,714) 
 Logit Pr (PHCC >0)	 OLS log (PHCC | 	
PHCC >0) 
 Coefficient 
(Standard	
Error)	 P-value	 Coefficient (Standard Error)	 P-value	
Age of HCC 
diagnosis 	
(δ 10 years)	
-0.20 (0.02)	 <0.001	 0.11 (0.05)	 0.04	
Gender	
Male	 Ref	 Ref	 Ref	 Ref	
Female	 0.15 (0.05)	 0.001	 0.01 (0.01)	 0.04	
Race/ethnicity	
White	 Ref	 Ref	 Ref	 Ref	
Black	 0.39 (0.07)	 <0.001	 0.01 (0.01)	 0.10	
Hispanic	 0.46 (0.07)	 <0.001	 0.02 (0.01)	 0.006 
Asian	 1.00 (0.08)	 <0.001	 0.10 (0.01)	 <0.001	
Other race	 0.58 (0.10)	 <0.001	 0.07 (0.01)	 <0.001	
Year of HCC diagnosis	
2003	 Ref	 Ref	 Ref	 Ref	
2004	 -0.16 (0.12)	 0.19	 -0.01 (0.01)	 0.68	
2005	 0.001 (0.11)	 0.99	 -0.02 (0.01)	 0.07	
2006	 -0.17 (0.11)	 0.14	 -0.01 (0.01)	 0.57	
2007	 -0.15 (0.11)	 0.17	 -0.004 (0.01)	 0.75 
2008	 -0.13 (0.11)	 0.24	 -0.01 (0.01)	 0.28 
2009	 -0.20 (0.11)	 0.07	 -0.02 (0.01)	 0.06 
2010	 -0.12 (0.11)	 0.27	 <-0.001 (0.01) 1.00 
2011	 -0.14 (0.11)	 0.19	 <-0.001 (0.01) 0.99	
2012	 -0.17 (0.11)	 0.11	 0.003 (0.01)	 0.82	
2013	 -0.07 (0.11)	 0.53	 0.03 (0.01)	 0.02	
Cirrhosis duration	
No diagnosis of 
cirrhosis	
Ref	 Ref	 Ref	 Ref	
Cirrhosis diagnosis 
within 3 years of 
HCC diagnosis	
0.94 (0.06) <0.001	 0.04 (0.01)	 <0.001	
Cirrhosis before 3 
year screening 
period	
0.81 (0.07)	 <0.001	 0.10 (0.01)	 <0.001	
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Table 6. Continued 
 Logit Pr (PHCC >0)	 OLS log (PHCC | 	
PHCC >0) 
HCC etiology	
No liver correlated 
conditions	
Ref	 Ref	 Ref	 Ref	
HBV	 -0.06 (0.06)	 0.32	 0.02 (0.01)	 0.004	
HCV	 0.20 (0.12)	 0.10	 0.03 (0.01)	 0.07	
Alcoholic fatty 
liver or alcoholic 
cirrhosis	
-0.06 (0.10)	 0.59	 0.01 (0.01) 0.21	
Other liver disease	 0.75 (0.08)	 <0.001	 0.04 (0.01)	 <0.001 
More than one liver 
correlated condition	
0.61 (0.06)	 <0.001	 0.06 (0.01)	 <0.001	
Ascites	
Yes	 0.17 (0.08)	 0.03	 0.01 (0.01)	 0.08	
No	 Ref	 Ref	 Ref	 Ref	
Hepatic encephalopathy	
Yes	 0.41 (0.09)	 <0.001	 0.05 (0.01)	 <0.001	
No	 Ref	 Ref	 Ref	 Ref	
NCI comorbidity index score	
None	 Ref	 Ref	 Ref	 Ref	
Low	 0.09 (0.12)	 0.42	 0.004 (0.81) 0.81	
Moderate	 0.20 (0.12)	 0.09 0.007 (0.02) 0.68	
High	 0.33 (0.12)	 0.004 0.01 (0.02)	 0.44	
Provider specialty visited	
Internal medicine/ 
family practice	
0.57 (0.10)	 <0.001	 0.02 (0.01)	 0.27	
Gastroenterology	 1.10 (0.05)	 <0.001	 0.06 (0.01)	 <0.001	
Hematology/	
oncology	
0.25 (0.05)	 <0.001	 0.01 (0.01)	 0.04	
Vascular/	
interventional 
radiology	
1.91 (0.11)	 <0.001	 0.03 (0.02)	 0.10 
General surgery	 0.30 (0.05)	 <0.001	 0.01 (0.01)	 0.13	
Other	 0.33 (0.11)	 0.004	 0.03 (0.02)	 0.04	
Practice arrangement of principal provider	
Solo practice	 Ref	 Ref	 Ref	 Ref	
Group practice	 -0.06 (0.05)	 0.23	 -0.01 (0.01)	 0.03	
Hospital	 -0.19 (0.09)	 0.03	 -0.001 (0.01)	 0.89	
Medical school	 -0.01 (0.23) 0.98	 0.03 (0.02)	 0.25	
Other	 -0.07 (0.08)	 0.36	 0.01 (0.01)	 0.39	
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Table 6. Continued 
 Logit Pr (PHCC >0)	 OLS log (PHCC | 	
PHCC >0) 
U.S. training status of principal provider	
Yes	 -0.11 (0.05)	 0.03	 -0.002 (0.01)	 0.63	
No	 Ref	 Ref	 Ref	 Ref	
Other	 -0.04 (0.15) 0.80	 -0.02 (0.02)	 0.37	
Constant	 -3.14 (0.29)	 <0.001	 0.12 (0.04)	 0.001	
 
In the multivariate tobit regression model, receipt of HCC screening was associated with 
similar factors found in the multivariate two-part regression model. HCC screening was 
associated with younger patient age, female gender, Asian race, longer length of time with 
known cirrhosis, presence of HCV, presence of other liver disease, presence of more than one 
liver correlated condition, presence of decompensated cirrhosis, moderate and higher 
comorbidity score and having visited any specialty provider (p<0.05). 
Results from the multivariate tobit regression model (Table 7) also illustrate that having 
seen a principal provider in a group practice or hospital setting was associated with increased 
HCC screening receipt (p<0.05). Conflicting results were found regarding having seen a 
principal provider that was trained in the United States. In the multivariate tobit regression 
model, the results of having seen a principal provider that was trained in the United States was 
similar to the logistic regression portion of the multivariate two-part regression model and was 
statistically significant (p<0.05). The direction was negative, indicating that having seen a 
principal provider that was not trained in the United States may suggest increased receipt of any 
HCC screening, however this was not statistically significant in the conditional OLS portion of 
the multivariate two-part regression model. Further, similar to the multivariate two-part 
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regression model, there was no difference in year of HCC diagnosis and overall the results were 
not statistically significant (p>0.05). 
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Table 7. Estimation results for predictors of change in HCC screening receipt using a 
multivariate tobit regression model (n=13,714) 
 Coefficient (Standard	
Error)	 P-value	
Age of HCC diagnosis 	
(δ 10 years)	
-0.03 (0.003)	 <0.001	
Gender	
Male	 Ref	 Ref	
Female	 0.03 (0.01)	 <0.001	
Race/ethnicity	
White	 Ref	 Ref	
Black	 0.06 (0.01)	 <0.001	
Hispanic	 0.07 (0.01)	 <0.001	
Asian	 0.20 (0.01)	 <0.001	
Other race	 0.12 (0.01)	 <0.001	
Year of HCC diagnosis	
2003	 Ref	 Ref	
2004	 -0.03 (0.02)	 0.16	
2005	 -0.01 (0.02)	 0.44	
2006	 -0.03 (0.02)	 0.11	
2007	 -0.02 (0.02)	 0.18	
2008	 -0.03 (0.02)	 0.11	
2009	 -0.04 (0.02)	 0.01	
2010	 -0.02  (0.02)	 0.30	
2011	 -0.02 (0.02)	 0.23	
2012	 -0.02 (0.02)	 0.18	
2013	 0.01 (0.02)	 0.49	
Cirrhosis duration	
No diagnosis of cirrhosis	 Ref	 Ref	
Cirrhosis diagnosis within 3 
years of HCC diagnosis	
0.15 (0.01)	 <0.001	
Cirrhosis before 3 year 
screening period	
0.18 (0.01)	 <0.001	
HCC etiology	
No liver correlated conditions	 Ref	 Ref	
HBV	 <0.001 (0.01)	 1.00	
HCV	 0.04 (0.02)	 0.02	
Alcoholic fatty liver or 
alcoholic cirrhosis	
0.003 (0.02)	 0.82	
Other liver disease	 0.12 (0.01)	 <0.001	
More than one liver 
correlated condition	
0.12 (0.01)	 <0.001	
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Table 7. Continued 
 Coefficient (Standard	
Error)	 P-value	
Ascites	
Yes	 0.03	 0.002	
No	 Ref	 Ref	
Hepatic encephalopathy	
Yes	 0.07 (0.01)	 <0.001	
No	 Ref	 Ref	
NCI comorbidity index score	
None	 Ref	 Ref	
Low	 0.02 (0.02)	 0.39	
Moderate	 0.04 (0.02)	 0.05	
High	 0.06 (0.02)	 0.002	
Provider specialty visited	
Internal medicine/ family 
practice	
0.09 (0.02)	 <0.001	
Gastroenterology	 0.20 (0.01)	 <0.001	
Hematology/	
oncology	
0.04 (0.01)	 <0.001	
Vascular/	
interventional radiology	
0.04 (0.01)	 <0.001	
General surgery	 0.04 (0.01) 	 <0.001	
Other	 0.07 (0.02)	 <0.001	
Practice arrangement of principal provider	
Solo practice	 Ref	 Ref	
Group practice	 -0.02 (0.01)	 0.02	
Hospital	 -0.03 (0.01)	 0.05	
Medical school	 0.02 (0.03)	 0.60	
Other	 -0.01 (0.01)	 0.66	
U.S. training status of principal provider	
Yes	 -0.02 (0.01)	 0.02	
No	 Ref	 Ref	
Other	 -0.01 (0.02)	 0.55	
Sigma	 0.30 (0.003)	 -	
 
3.4 Discussion 
Several patient and provider characteristics were found to be associated with HCC 
screening receipt. Younger patient age was associated with receipt of any HCC screening, 
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however after excluding patients without any screening the results changed from negative to 
positive. In the multivariate tobit regression model, younger patient age was associated with the 
likelihood of HCC screening. These findings were somewhat consistent with literature. Davila 
and colleagues found that relatively younger cirrhotic patients were more likely to receive 
consistent screening compared to older cirrhotic patients.55 This may be attributed to younger 
patient age and the association in recognition of liver disease.29 Providers may also be less likely 
to order screening in older patients given the perceived notion that these patients would not 
benefit from screening.23,24,140 However, in a more recent study in 2015, Singal et al. found that 
age was not associated with inconsistent screening.16 Ahmed Mohammed et al. also did not find 
age to impact receipt of HCC screening in Minnesota residents seen at the Mayo Clinic in 
Rochester, Minnesota and his results were not statistically significant.47 Findings from this study 
illustrate that younger patient age was associated with the likelihood of HCC screening and 
suggest further research is needed on the preferences of HCC screening and the accompanying 
processes in older patients.140  
The result that female gender was associated with HCC screening receipt in both 
regression models was somewhat consistent with findings in literature, and this was still true at 
the p<0.05 level after excluding patients without any screening in the sample. A meta-analysis 
study by Singal et al. found other studies that evaluated the impact of gender found no 
differences in HCC screening between males and females.12 This finding was consistent with 
results from a study referenced previously by Ahmed Mohammed and colleagues.47 However, a 
study by Farinati and colleagues found female HCC patients were diagnosed more frequently by 
screening, which may be due to a higher compliance with HCC screening rather than to 
  72 
biological differences.141 Future research may be needed to validate gender differences and 
whether female HCC patients are more compliant with HCC screening compared to males. 
Race was found to be associated with HCC screening receipt in both the multivariate 
two-part regression model and the multivariate tobit regression model. Although Ahmed 
Mohammed et al. did not find race to impact receipt of HCC screening,47 we found that being of 
Asian race in this study was greatly associated with HCC screening receipt, and was agreeable 
with findings from Davila and colleagues.55 Ahmed Mohammed et al. may not have found race 
to be greatly associated with HCC screening, perhaps due to the fact that approximately 81% of 
Minnesota residents were white compared to 61.6% in this sample.47,142 
Differences in the association between race and HCC screening may be largely because 
Asians have the highest incidence of HBV infection and subsequently an increased knowledge of 
HBV and the importance HCC screening, given HBV infection is more common in eastern Asian 
countries and most Asians with HCC were born outside the United States.17,41,143–145 Thus, gaps 
in HCC screening in the United States may include incomplete testing of foreign-born 
Asians.17,143,144 In the United States, HBV infection accounts for up to 15% of all HCC cases and 
reports illustrate 41% to 84% of HBV-related HCC occur in Asians.143 A report from Los 
Angeles, California found that in Asians, 74% of HCC was linked to HBV.17  
Surprisingly, whites were less likely to receive HCC screening receipt in comparison to 
Blacks, Hispanics and other race in this study. These findings were somewhat contradictory to 
current literature. Singal et al. found lower rates of HCC screening among African Americans.16 
Another study using the national VA database further confirmed African Americans were less 
likely to receive HCC screening compared to Whites, and other non-Whites had a trend toward 
lower screening rates.115 In univariate analysis, Ahmed Mohammed et al. found non-whites to be 
  73 
associated with increased HCC screening receipt, and his results were statistically significant.47 
Results from this study were based on race/ethnicity information from the Medicare Enrollment 
Database (EDB) obtained from the Social Security Administration (SSA) records, which has 
been questioned in literature regarding validity.146,147 Thus, further research may be necessary to 
properly assess differences in race/ethnicity classification and how this in turn would affect HCC 
screening receipt.  
Overall, there was no difference between HCC screening receipt and HCC diagnosis 
years. All years of HCC diagnosis yielded slightly lower HCC screening rates compared to 
baseline (2003), except for more recent years (2012 and 2013) regarding the intensity of HCC 
screening among patients screened. This may be attributed to a latent response to revised 
guidelines in HCC management in 2005 by The American Association for the Study of Liver 
Diseases (AASLD).55,68,102 
Receipt of HCC screening was associated with a number of clinical factors, including 
longer length of time with known cirrhosis, presence of other liver disease, presence of more 
than one liver correlated condition, and presence of decompensated cirrhosis (ascites and hepatic 
encephalopathy) (p<0.05). These findings were again, consistent with findings in literature. 
Davila and colleagues reported that patients who had a diagnosis of cirrhosis for a longer 
duration prior to their HCC diagnosis were also more likely to receive screening.55 Ahmed 
Mohammed et al. found similar results regarding patients with decompensated cirrhosis, as 
evidenced by hepatic encephalopathy to be associated with increased HCC screening 
utilization.47  
Contrastingly, Singal and colleagues found ascites to be associated with increased HCC 
screening utilization rather than hepatic encephalopathy.29,47 Nonetheless, both hepatic 
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encephalopathy and ascites suggest that patients with more decompensated cirrhosis were more 
likely to be screened for HCC, perhaps because their liver disease is more symptomatic and 
obvious.47 Unfortunately, patients with decompensated cirrhosis may not have any long-term 
benefit from HCC screening due to advanced disease progression.12,17,23,47 A previous diagnosis 
of HBV was only found to be associated with screening receipt in the conditional OLS model, 
while a previous diagnosis of HCV was only statistically significant in the multivariate tobit 
regression model. Results from both regression models were surprising given most cases of HCC 
are associated with HBV or HCV infections.4 
Receipt of any HCC screening was associated with having been seen by a 
gastroenterologist or vascular/interventional radiologist (p<0.001). These findings were 
consistent with literature. Davila and colleagues also discovered that patients seen by a 
gastroenterologist or hepatologist were more likely to receive consistent screening compared to 
patients seen by internal medicine or family practice providers.55  
Internal medicine or family practice providers follow most patients diagnosed with 
cirrhosis, while gastroenterologists or hepatologists only follow 20% to 40% of these 
patients.16,23,68,148,149 Approximately 92.5% of all patients in this sample saw an internal medicine 
or family practice provider compared to half (51.3%) of all patients who saw gastroenterologists 
or hepatologists in the 3 years prior to HCC diagnosis.  
Given having seen a gastroenterologists or hepatologists was found to be greatly 
associated with HCC screening receipt after excluding patients without any screening in this 
study, the results suggest that internal medicine or family practice providers should refer patients 
at risk for HCC to gastroenterologists or hepatologists. Another prominent issue is limited 
availability of subspecialty clinics in many areas of the U.S., implicating lack of access to these 
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specific providers.12,52 Therefore, education for internal medicine or family practice providers are 
highly recommended so they can properly identify and care for patients at risk. Further, internal 
medicine or family practice providers need to understand the importance of HCC screening, as 
well as the best modality and how often to screen given internal medicine or family practice 
providers follow most patients in the U.S. with cirrhosis.16,64 
In a web-based survey study by Dalton-Fitzgerald and colleagues, more than 90% of 
family practice providers reported that they felt they were responsible for HCC screening, 
however were unaware of how to best perform screening and reported barriers to effective 
implemetation.64 The study found that family practice providers believed AFP was an effective 
screening test when used alone, and two thirds of providers reported performing annual instead 
of biannual HCC screening.64 These misconceptions regarding HCC screening by family practice 
providers subsequently lead to profound underutilization of HCC screening.64  
Typically internal medicine or family practice providers take on the role as gatekeepers 
and facilitate access to specialty care and therefore should be educated on the benefits of 
referring patients at risk for HCC to gastroenterologists or hepatologists.150 Further studies are 
needed to characterize internal medicine or family practice providers’ attitudes and knowledge 
nationally in regard to HCC screening receipt.  Understanding internal medicine or family 
practice providers’ attitudes and knowledge regarding referrals to specialty care, as well as 
quantifying these rates of referrals to ensure appropriate patients are receiving timely access to 
care specific for HCC are also crucial.12,16 
3.4.1 Limitations 
To date, not many studies in literature have characterized the influence of provider-
related factors on HCC screening receipt using large administrative data. 
  76 
it examines the association between HCC screening receipt and the influences of provider 
characteristics. Given these qualities, there are limitations worth noting. Patients could have had 
HCC without record of an ICD-9 code prior to their provider visit. Further, it is difficult to 
determine the true association between HCC screening and provider specialty, given there is no 
way to identify exactly which provider ordered screening for HCC in administrative claims data. 
The results of this study may only be representative of the Medicare Fee-For-Service 
(FFS) population and cannot be generalizable to a wider population given Medicare data does 
not encompass claims for care provided in other settings, such as the Veterans Administration or 
Medicare Part C (aka Medicare Advantage) plans, care for persons with Medicare as the 
secondary payer, and out of pocket expenditures for services not covered.118,119  
It is also suggested that more thorough, precise documentation in large population based, 
administrative data such as SEER-Medicare is necessary in order to determine the true intent of 
abdominal ultrasound tests for HCC screening. As mentioned in a previous study, despite 
applying the intent algorithm to the data, this method of measurement is still limited since it is 
unknown whether screening was administered solely for HCC screening purposes without a 
retrospective medical chart review.  
3.5 Conclusion 
The second study in this dissertation identifies patient and provider factors that influence 
HCC screening receipt using the previously developed PUTD measure in a large population 
based administrative data in hopes to guide intervention strategies to improve future HCC 
screening receipt. Various intervention strategies to detect unrecognized cirrhosis in at risk 
patients, as well as interventions to improve testing for patients at risk for liver diseases 
including HCV and NASH are highly encouraged. Further, interventions to improve 
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classification measures for race/ethnicity categories to assess accurate racial/ethnic disparities 
and interventions to improve knowledge about HCC screening among primary care providers are 
fundamental in order to understand and improve HCC screening rates. 
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4. ASSOCIATION OF HCC SCREENING ON EARLY STAGE DIAGNOSIS AND 
OVERALL SURVIVAL  
 
4.1 Introduction 
HCC mortality has rapidly increased between 2006 and 2010 with all ages in all 
racial/ethnic groups.18 While death rates for most cancer sites are declining in the U.S. for both 
men and women of all major racial and ethnic groups, deaths from HCC increased by an average 
of 3% per year.5 To mitigate this growing public health issue, screening for HCC is 
recommended due to growing evidence of its efficacy that it reduces incidence and 
mortality.61,117 Patients with chronic liver disease often remain asymptomatic for many years, or 
even decades, with progressive liver damage until they develop cirrhosis or even late stage 
HCC.65 Thus, screening for HCC is highly encouraged since HCC prognosis heavily depends on 
tumor stage at the time of diagnosis and tumors can be found at early stages if at risks patients 
are screened routinely.19,23  
Countries with a comprehensive program for HCC risk identification and surveillance, 
mainly in Japan and Taiwan, revealed that approximately 70% of HCC was detected at very 
early or early stages.47,152 Findings from The Global HCC BRIDGE study of incidence and 
outcomes confirm that HCC prognosis and improved survival can be achieved from early tumor 
detection as a result of HCC screening.47,152 Unfortunately, findings regarding the effectiveness 
of HCC screening are still mixed. Current studies report conflicting conclusions regarding the 
benefits of HCC screening. 
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Thus, the third and final study of this dissertation characterizes the association of HCC 
screening receipt with early tumor detection and overall survival in a population based sample of 
patients in the United States.  
Background 
A few studies in literature have noted the efficacy and benefits of HCC screening on 
early tumor detection and survival, however these studies focused only on patients with HBV 
and HCV.  
In HBV patients, Zhang and colleagues found that screening reduced HCC related 
mortality by 37%, despite poor adherence.67,153 A randomized population based study found 
more early stage cancers in the screened group compared to the non-screened group, however the 
difference did not affect long-term survival benefit, possibly due to underutilization of curative 
treatment.67,154 The latter study however had a small sample size, which could have led to lower 
statistical power between screening and long-term survival.155 In patients with HCV, El-Serag 
and colleagues found patients who had increased screening tests had the longest survival, while 
patients who received no screening had the shortest survival.156 A study from Taiwan reported 
HCC patients with HBV or HCV who received routine or opportunistic (incidental or non 
hepatic purposes) screening had a 63% reduction in mortality compared to symptomatic 
diagnosis.101,102,151 
Little studies have focused on the effect of screening and survival in overall HCC 
patients. One study from Milan, Italy found screening to be associated with an increase in 
survival in patients with compensated cirrhosis.45 Their study suggests improved patient outcome 
in those who were detected with HCC under surveillance.45 Other studies in literature have 
suggested poor efficacy of HCC surveillance was attributed to the presence of medical and 
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psychological co-morbid disorders in patients, as well as low utilization among at risk 
patients.52,157 There were no differences in receipt of treatment or survival between HCC patients 
who received semiannual vs. annual HCC screening in one study.158 Given radiology technicians 
typically conduct these abdominal ultrasounds and have very limited medical training in the 
clinical setting, high variability in technique of the procedure may be one of the factors that 
contribute to poor efficacy of HCC screening.31,157 This is especially true in local community 
centers where there is more irregularity in “operator” experience and technic.157  
4.2 Methods 
4.2.1 Data Source 
The Surveillance, Epidemiology and End Results (SEER)-Medicare data linked to the 
American Medical Association (AMA) Master File was used to characterize the association of 
HCC screening receipt with early tumor detection and overall survival. 
The American Medical Association (AMA) Master File includes current and historical 
data for more than 1.4 million physicians, residents and medical students in the United States, 
Puerto Rico, Virgin Islands and certain Pacific Islands. Data includes information about 
education, training and professional certification and credentialing.132,133 The SEER program 
collects data on incident cancer cases from 20 cancer registries (state, central, metropolitan, and 
the Alaska Native registries), which account for approximately 28% of the population in the 
United States.69,72 Linked SEER-Medicare data holds clinical, demographic and survival 
information for persons with cancer from the SEER program of cancer registries with Medicare 
claims information on covered health services from time of Medicare eligibility until death.  
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4.2.2 Study Population 
Logistic regression sample 
For multivariate logistic regression, patients diagnosed with HCC from 2003 to 2013 
were identified using ICD-O 8170. Inclusion eligibility for this study encompassed: 1) 
diagnostically confirmed HCC (positive histology, cytology, laboratory test/marker, positive 
radiology tests) 2) enrollment with Medicare Part A and B enrollment at least 3 years prior to 
HCC diagnosis and 3) no enrollment in Medicare health maintenance organizations (HMOs) 
since Medicare HMO plans were not required to submit individual claims information for 
services to the Centers for Medicare and Medicaid Services (CMS).55,71 Similar to the second 
study, patients who exclusively saw emergency medicine physicians were excluded from 
analysis given this is not representative of preventative care and screening for HCC. Physicians 
with no information regarding specialty, practice arrangement, or medical school graduation date 
were also not included in this study. This detail of sample selection is noted in the first study. 
The final study sample comprised of 13,714 SEER-Medicare patients diagnosed with HCC. A 
subsample of patients with known cirrhosis was also used to analyze the impact of screening, 
early tumor detection and survival in this specific at risk population (n=2,972).  
4.2.3 Patient, Milan Criteria and Cirrhosis Duration Characteristics 
 Information on patient, Milan Criteria and cirrhosis duration characteristics were 
analyzed as independent variables for analyses. 
Patient Characteristics 
In the SEER Patient Entitlement and Diagnosis Summary File (PEDSF file), patient 
characteristics such as age at HCC diagnosis, gender, race/ethnicity, metropolitan area (based on 
Rural/Urban Continuum Codes (RUCC) coded by SEER), Census poverty indicator of patient's 
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residence (proxy for socioeconomic status), and year of HCC diagnosis were available and 
acquired for analysis.101,102 Liver disease etiology (hepatitis B virus (HBV), hepatitis C virus 
(HCV), alcoholic liver disease, hemochromatosis, or other) and duration of cirrhosis were also 
identified in Medicare claims (MEDPAR, NCH, Outpatient files) for each patient. The variable, 
cirrhosis duration was constructed and patients were stratified into subsequent duration groups 
(Refer to first study of this dissertation). Liver dysfunction characteristics were determined using 
Medicare claims information billed for ascites or hepatic encephalopathy at least 6-months prior 
to HCC diagnosis. Pharmacy claims information billed for spironolactone or furosemide to 
determine whether a patient had ascites, and pharmacy claims information billed for lactulose 
and rifaximin to determine whether a patient had hepatic encephalopathy from the Medicare Part 
D Data file were also collected. The National Cancer Institute (NCI) Comorbidity Index was 
used to measure non-cancer comorbidities in patients.108,109 Diagnosis and procedure codes to 
calculate this index were provided by the National Cancer Institute (NCI) and subsequently used 
to identify comorbidities 1 year prior to HCC diagnosis.108,110 The Milan Criteria variable, which 
was previously constructed in the first study of this dissertation was also used.  
4.2.4 Provider Characteristics 
 Information on provider characteristics were compiled and used as independent variables 
for analyses, similar to the second study of this dissertation. Provider level characteristics were 
aggregated to the patient level. For each patient, variables indicating whether they saw a specific 
category of clinic provider (internal medicine/family practice, gastroenterology, 
hematology/oncology, vascular/interventional radiology, general surgery and other) during the 3-
year screening period were constructed in the same manner as discussed in the second study. 
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The most commonly seen clinic provider or the patient’s principal provider was also 
determined during the study period in order to measure other provider characteristics that may be 
attributable to HCC screening receipt. For this patient’s principal provider, practice arrangement, 
year of graduation and U.S. training status was obtained.55 Practice arrangement was categorized 
as solo practice, group practice, hospital-based, medical school affiliated, or other.  
Patients were not included in the sample if any of the patient, tumor, cirrhosis and 
provider characteristics discussed in this study were missing. Further, missing variables were 
imputed using similarly available variables if possible. 
4.2.5 Statistical Analysis 
In order to examine overall survival, HCC diagnosis date was used as time of entry, and 
follow up was censored on either the date of death or December 31st, 2014. The date of death 
was assigned using the variable month and year date of death in the SEER data. If the SEER date 
of death was unavailable, Medicare month and year date of death was then used. 
To evaluate the association between HCC screening receipt and clinical outcomes 
including a) early tumor detection (defined as within Milan Criteria) and b) overall survival, 
simple and multivariate logistic regression and Cox proportional hazards model were used to 
examine predictors of cause-specific death, respectively. Cause of death was identified using 
ICD codes, available in the SEER PEDSF file.  
For these analyses, the categorical screening variable (consistent screening vs. 
inconsistent screening vs. no screening) was used to simplify clinical interpretation of results, as 
well as allow for easy comparison to assess degree of HCC screening with respect to prior 
studies in literature. We constructed Kaplan-Meier survival curves to calculate time-to-death, 
with follow-up censored at the end of the study period. Crude and adjusted hazard ratios (HR) 
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with 95% confidence intervals (95% CI) were estimated. SEER-Medicare data were right-
censored since data were approximately 2 to 3 years old.6. In order to distinguish ultrasound tests 
performed for the purposes of HCC screening, the validated algorithm previously described in 
the first study was applied as a sensitivity analysis to all portions of this study and results are 
shown in the appendix section.55,82 
Heteroskedasticity was assessed to check for any inconsistent variance in residuals and 
multicollinearity was also tested between pairs of coefficients to resolve any collinearity issues 
using the variance inflation factor (VIF). All analyses were conducted using STATA 14.0 
(StataCorp, College Station, TX, USA) and SAS 9.4 (SAS Institute Inc., Cary, NC). The study 
protocol was approved by the Institutional Review Board of Texas A&M University and the 
Institutional Review Board within the Division of Cancer Control & Population Sciences at the 
U.S. National Cancer Institute (NCI).  
4.3 Results 
4.3.1 Descriptive Statistics 
Approximately, 89.7% (n=11,314) of HCC patients died at the time of follow up, and 
1,105 (8.1%) HCC patients and 175 (5.9%) HCC patients with cirrhosis died within 1 month 
after diagnosis. The number of patients with HCC almost doubled in 10 years, from 868 patients 
in 2003 to 1,531 patients in 2013. The mean age of patients was 73 years and approximately 67% 
were men. The population was predominantly White non-Hispanic (62%), followed by Hispanics 
(13%), African American non-Hispanic (10%), and Asian non-Hispanic (9%) and Other Race 
(6%). A majority of patients in the sample resided in metropolitan areas and 31% of the 
population were living 10% to <20% below the poverty line. Almost half of HCC patients (42%) 
did not have any etiology of liver disease and the most common etiology of liver disease was 
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hepatitis B virus (HBV) infection (21.3%). Approximately 21.0% of HCC patients had more than 
one liver correlated condition. Less than 15% of patients had evidence of hepatic 
decompensation (ascites and hepatic encephalopathy).  
More than half (57%) of patients had unrecognized cirrhosis at time of HCC presentation, 
22% of patients were diagnosed with cirrhosis prior to the study period and 21% were diagnosed 
with cirrhosis during the study period. About half (51.4%) had more than one liver correlated 
condition and less than 15% did not have any etiology of liver disease prior to HCC diagnosis. 
Roughly 12.0% had alcoholic fatty liver or alcoholic cirrhosis, followed by 11.3% of patients 
who had a diagnosis of other liver disease. Nearly 7.2% of patients had hepatitis B virus (HBV) 
infection and 3.6% had hepatitis C virus (HCV) infection prior to HCC diagnosis. Almost a third 
of patients had evidence of hepatic decompensation in this sample, with 28.5% having ascites 
and 29.6% having hepatic encephalopathy prior to HCC diagnosis. 
4.3.2 Diagnosis of HCC Within Milan Criteria and Survival 
Approximately one-third (35.1%; n=4,813) of HCC patients in the final study sample 
were diagnosed at an early stage within Milan Criteria. Of patients with known cirrhosis prior to 
HCC presentation, approximately one-half (56.2%) were detected at an early stage within Milan 
Criteria. 
There were significant differences in survival for patients who were diagnosed with HCC 
within Milan Criteria. The mean survival time for patients diagnosed at an early stage within 
Milan Criteria was double the survival time in comparison to patients diagnosed outside of Milan 
Criteria (30 months vs. 15 months, respectively) and both results were statistically significant at 
p<0.05. Mean survival results in months are summarized in Table 8 below. 
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Table 8. Mean survival time in months for HCC patients diagnosed within and outside Milan 
Criteria (n=13,714) 
 Mean time survived in 
months (Standard Error) 
Within Milan Criteria 29.8 (0.57) 
Outside Milan Criteria 14.6 (0.27) 
Milan Criteria - Single tumor <5cm or 2 to 3 tumors all <3cm with no evidence of extrahepatic involvement or 
metastasis. 
 
In known cirrhosis patients, the mean survival time for patients diagnosed at an early 
stage within Milan Criteria was more than double the survival time in comparison to patients 
diagnosed outside of Milan Criteria (32 months vs. 13 months, respectively) and both results 
were statistically significant at p<0.05. Mean survival results in months are summarized for the 
subset of patients with known cirrhosis in Table 9 below. 
 
Table 9. Mean survival time in months for HCC patients with known cirrhosis diagnosed within 
and outside Milan Criteria (n=2,972) 
 Mean time survived in months 
(Standard Error) 
Within Milan Criteria 32.0 (1.00) 
Outside Milan Criteria 12.8 (0.58) 
Milan Criteria - Single tumor <5cm or 2 to 3 tumors all <3cm with no evidence of extrahepatic involvement or 
metastasis. 
 
The following figure (Figure 11) illustrate Kaplan-Meier estimates or non-parametric 
unadjusted survival estimates for all patients who were diagnosed with HCC within Milan 
Criteria. The Hall-Wellner bands illustrate the 95% confidence intervals. Kaplan-Meier estimates 
for patients with known cirrhosis who were diagnosed with HCC within Milan Criteria is also 
shown below (Figure 12).82 Visually, both figures illustrate increased survival times for patients 
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who were diagnosed with HCC within Milan Criteria. This influence is further magnified in 
patients with known cirrhosis as portrayed in the red shaded curve in Figure 12. Overall survival 
differences were statistically significant between the two groups and patients diagnosed with 
HCC outside of Milan Criteria had the poorest survival (p<0.001). Right censoring is indicated 
by the + mark in the Kaplan-Meier curve. 
 
Figure 11. Survival estimates of all patients diagnosed with HCC within Milan Criteria 
(n=13,714) 
 
Milan Criteria - Single tumor <5cm or 2 to 3 tumors all <3cm with no evidence of extrahepatic involvement or 
metastasis. 
This figure illustrates survival estimates with 95% confidence interval bands among all patients 
diagnosed with HCC from the years of 2003 to 2013 within and outside Milan Criteria. 
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Figure 12. Survival estimates of known cirrhosis patients with HCC within Milan Criteria 
(n=2,972) 
 
Milan Criteria - Single tumor <5cm or 2 to 3 tumors all <3cm with no evidence of extrahepatic involvement or 
metastasis. 
This figure illustrates survival estimates with 95% confidence interval bands among known cirrhosis 
patients diagnosed with HCC from the years of 2003 to 2013 within and outside Milan Criteria. 
 
4.3.3 Association Between Screening Receipt and Early Tumor Detection Using Multivariate 
Logistic Regression Model 
 In multivariate logistic regression analysis assessing HCC screening receipt (consistent 
screening vs. inconsistent screening vs. no screening) on early tumor detection within Milan 
Criteria, patients with consistent screening (adjusted OR 2.10; 95% CI 1.79-2.47) and 
inconsistent screening (adjusted OR 1.35; 95% CI 1.24-1.48) were associated with early tumor 
detection compared to no screening (Table 10).  
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In known cirrhosis patients, receipt of consistent screening (adjusted OR 2.47; 95% CI 
1.92-3.18) and inconsistent screening (adjusted OR 1.73; 95% CI 1.43-2.10) was associated with 
early tumor detection, adjusted for other factors, and these results were statistically significant 
(Table 10). After applying the screening intent algorithm in sensitivity analysis, multivariate 
logistic regression model results were very similar and adjusted OR results were slightly higher 
after application of screening algorithm. These results are shown in Appendix Table 10A.  
 
Table 10. Results from multivariate logistic regression model assessing HCC screening receipt 
on Milan Criteria (Diagnosis years 2003 to 2013) 
 Primary sample (n=13,714)	 Cirrhosis sample (n=2,972)	
 Crude 
OR	
Adjusted 
OR	
P-
value†	
95% 
CI†	
Crude 
OR	
Adjusted 
OR	
P-
value†	
95% 
CI†	
Consistent 
screening*	
5.16	 2.10	 <0.001	 1.79-
2.47	
2.97	 2.47	 <0.001	 1.92-
3.18	
Inconsistent 
screening**	
2.17	 1.35	 <0.001	 1.24-
1.48	
1.98	 1.73	 <0.001	 1.43-
2.10	
No 
screening	
Ref	 Ref	 Ref	 Ref	 Ref	 Ref	 Ref	 Ref	
*Having ≥1 abdominal ultrasound per calendar year 
**Having ≥1 abdominal ultrasound during the study period but less than annually 
†For adjusted OR results 
NOTE: Adjusted for age, gender, year of HCC diagnosis, length of time with known cirrhosis, liver 
etiology, hepatic encephalopathy, some provider specialty visited, practice arrangement of principal 
provider, and U.S. training status in primary sample. Adjusted for gastroenterology provider visited and 
practice arrangement of principal provider only in cirrhosis sample. 
 
  
Results from the full adjusted multivariate logistic regression model (Table 11) indicated 
that other patient characteristics including younger age of diagnosis (Adjusted OR 0.98; 95% CI 
0.98-0.99), female gender (Adjusted OR 1.14; 95% CI 1.05-1.24), having longer length of time 
with known cirrhosis (Adjusted OR 2.01; 95% CI 1.81-2.24; Adjusted OR 2.19; 95% CI 1.95-
2.47), presence of having other liver disease (Adjusted OR 1.22; 95% CI 1.06-1.41) or more than 
one liver correlated condition (Adjusted OR 1.26; 95% CI 1.12-1.41), and presence of hepatic 
encephalopathy (Adjusted OR 1.25; 95% CI 1.09-1.43) were associated with early tumor 
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detection within Milan Criteria. All years of HCC diagnosis were statistically significant, 
however overall there were no differences in the influence between HCC screening receipt and 
diagnosis within Milan Criteria across all years (no years were different from the reference 
category (2003); p<0.05).  
Provider characteristics including having visited a gastroenterology provider (Adjusted 
OR 1.32; 95% CI 1.21-1.44) and having seen a principal provider who was employed in the 
hospital (Adjusted OR 1.11; 95% CI 0.95-1.29) and medical school (Adjusted OR 1.46; 95% CI 
1.00-2.14) setting and was trained in the United States (Adjusted OR 1.14; 95% CI 1.05-1.24) 
were associated with early tumor detection within Milan Criteria. All results were statistically 
significant at p<0.05. Full logistic regression model results are reported in Table 11 below and in 
Appendix Table 11A and 11B. 
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Table 11. Full results from adjusted logistic regression model in all patients assessing HCC 
screening receipt on Milan Criteria (Diagnosis years 2003 to 2013; n=13,714) 
 Adjusted OR	 P-value	 95% CI	
Screening group 
Consistent screening*	 2.10	 <0.001	 1.79-2.47	
Inconsistent screening**	 1.35	 <0.001	 1.24-1.48	
No screening	 Ref	 Ref	 Ref	
Age of HCC diagnosis 0.98 <0.001 0.98-0.99 
Gender 
Male	 Ref Ref Ref 
Female	 1.14 0.001 1.05-1.24 
Year of HCC diagnosis 
2003	 Ref Ref Ref 
2004	 1.78 <0.001 1.42-2.23 
2005	 1.69 <0.001 1.36-2.11 
2006	 1.69 <0.001 1.36-2.10 
2007	 1.59 <0.001 1.28-1.96 
2008	 1.70 <0.001 1.38-2.10 
2009	 1.67 <0.001 1.36-2.06 
2010	 2.12 <0.001 1.73-2.60 
2011	 1.91 <0.001 1.56-2.34 
2012	 1.91 <0.001 1.56-2.34 
2013	 2.14 <0.001 1.75-2.62 
Cirrhosis duration 
No diagnosis of cirrhosis	 Ref Ref Ref 
Cirrhosis diagnosis within 3 years 
of HCC diagnosis	
2.01 <0.001 1.81-2.24 
Cirrhosis before 3 year screening 
period	
2.19 <0.001 1.95-2.47 
HCC etiology 
No liver correlated conditions	 Ref Ref Ref 
HBV	 0.99 0.89 0.89-1.11 
HCV	 1.22 0.08 0.98-1.53 
Alcoholic fatty liver or alcoholic 
cirrhosis	
1.16 0.10 0.97-1.40 
Other liver disease 1.22 0.007 1.06-1.41 
More than one liver correlated 
condition	
1.26 <0.001 1.12-1.41 
Hepatic encephalopathy 
Yes 1.25 0.001 1.09-1.43 
No Ref Ref Ref 
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Table 11. Continued 
Provider specialty visited 
Internal medicine/family practice	 0.79 0.002 0.68-0.91 
Gastroenterology	 1.32 <0.001 1.21-1.44 
Practice arrangement of principal provider 
Solo practice	 Ref Ref Ref 
Group practice	 1.04 0.41 0.95-1.13 
Hospital	 1.11 0.19 0.95-1.29 
Medical school	 1.46 0.05 1.00-2.14 
Other	 1.03 0.66 0.90-1.19 
U.S. training status of principal provider 
Yes 1.14 0.002 1.05-1.24 
No Ref Ref Ref 
Other 1.20 0.19 0.92-1.56 
Constant 0.50 <0.001 0.34-0.73 
*Having ≥1 abdominal ultrasound per calendar year 
**Having ≥1 abdominal ultrasound during the study period but less than annually 
 
4.3.4 Association Between Screening Receipt and Overall Survival Using Multivariate Cox 
Proportional Hazards Model 
 There were significant differences in survival time for patients who received consistent 
and inconsistent screening for HCC. The mean survival time for HCC patients who received 
consistent screening was 30 months, followed by approximately 23 months for patients who 
received inconsistent screening prior to HCC diagnosis. The average survival time for patients 
who did not receive any screening was about 16 months and all results were statistically 
significant at p<0.05. Results for mean survival time in months for all HCC patients stratified by 
screening groups are summarized in Table 12 below. In sensitivity analysis, there was a slight 
increase in mean time survived in months after application of screening algorithm, however the 
trend of results remained similar. Results are shown in Table 12A in the appendix section. 
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Table 12. Mean survival time in months for all HCC patients by screening groups (n=13,714) 
 Mean time survived in months 
(Standard Error) 
Consistent screening* 29.6 (1.34) 
Inconsistent screening** 22.8 (0.45) 
No screening 16.2 (0.33) 
*Having ≥1 abdominal ultrasound per calendar year 
**Having ≥1 abdominal ultrasound during the study period but less than annually 
 
  
In HCC patients with known cirrhosis, the average survival time for patients who did not 
receive any screening was about 18 months (p<0.05). Patients with HCC survived approximately 
23 months on average if they received inconsistent screening prior to HCC diagnosis (p<0.05).  
HCC patients who received consistent screening had longer survival, with an average of 29 
months. Mean time survived for known cirrhosis patients are summarized below in Table 13. 
Similar to previous sensitivity analysis results, there was a slight increase in mean time survived 
(months) in HCC patients who received consistent and inconsistent screening after application of 
screening intent algorithm. Overall, findings remained very similar with the poorest survival in 
patients who did not receive any screening for HCC. Results with application of the screening 
intent algorithm are shown in Table 13A in the appendix section. 
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Table 13. Mean survival time in months for known cirrhosis HCC patients by screening groups 
(n=2,972) 
 Mean time survived in months 
(Standard Error) 
Consistent screening* 29.3 (1.76) 
Inconsistent screening** 22.8 (0.81) 
No screening 17.5 (0.89) 
*Having ≥1 abdominal ultrasound per calendar year 
**Having ≥1 abdominal ultrasound during the study period but less than annually 
 
Overall, screening receipt was associated with improved survival and results were 
statistically significant (p<0.05). The following figures below (Figure 13 and Figure 14) 
illustrate Kaplan-Meier estimates or non-parametric unadjusted survival estimates for all patients 
and known cirrhosis patients in the sample who received HCC screening (consistent screening 
vs. inconsistent screening vs. no screening) respectively. The Hall-Wellner method is used to 
compute the 95% confidence bands. Visually, the figures illustrate increased survival for patients 
who received consistent screening, followed by patients who received inconsistent screening. 
This influence is amplified in the known cirrhosis subsample of patients. Overall survival 
differences were statistically significant among screening groups and patients who received 
consistent and inconsistent HCC screening had better survival (p<0.001). 
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Figure 13. Survival estimates for all patients by receipt of HCC screening (n=13,714) 
 
Consistent Screening=Having ≥1 abdominal ultrasound per calendar year 
Inconsistent Screening=Having ≥1 abdominal ultrasound during the study period but less than annually 
This figure illustrates survival estimates with 95% confidence interval bands among all patients 
diagnosed with HCC from the years of 2003 to 2013 who received consistent, inconsistent and no 
screening in the 3 years prior to their HCC diagnosis. 
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Figure 14. Survival estimates for known cirrhosis patients by receipt of HCC screening 
(n=2,972) 
 
Consistent Screening=Having ≥1 abdominal ultrasound per calendar year 
Inconsistent Screening=Having ≥1 abdominal ultrasound during the study period but less than annually 
This figure illustrates survival estimates with 95% confidence interval bands among known cirrhosis 
patients diagnosed with HCC from the years of 2003 to 2013 who received consistent, inconsistent and no 
screening in the 3 years prior to their HCC diagnosis. 
 
 
In multivariate Cox proportional hazards model analysis of time to death and screening 
receipt was associated with improved survival. Compared with no screening, consistent (adjusted 
HR 0.72; 95% CI 0.66 - 0.78) and inconsistent (adjusted HR 0.84; 95% CI 0.81 - 0.88) screening 
was associated with lower mortality (Table 14). A similar trend in results was observed in the 
subset of patients with a diagnosis of cirrhosis. Consistent (adjusted HR 0.73; 95% CI 0.64-0.82) 
and inconsistent screening (adjusted HR 0.87; 95% CI 0.80-0.96) was associated with lower 
mortality compared with no screening and these results were statistically significant at p>0.05 
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(Table 14). Full results are shown in the appendix section (Table 14A and 14B) and a summary 
table illustrating the association with screening receipt and overall survival is also shown in the 
appendix section (Table 14C). 
 
Table 14. Results from Cox proportional hazards model for association with screening receipt 
and overall survival (Diagnosis years 2003 to 2013) 
 Primary sample (n=13,714)	 Cirrhosis sample (n=2,972)	
	 Crude 
HR	
Adjusted 
HR	
P-value	 95% 
CI	
Crude 
HR	
Adjusted 
HR	
P-value	 95% 
CI	
Consistent 
screening*	
0.61	 0.72	 <0.001	 0.66-
0.78	
0.65	 0.73	 <0.001	 0.64-
0.82	
Inconsistent 
screening**	
0.77	 0.84	 <0.001	 0.81-
0.88	
0.81	 0.87	 0.005	 0.80-
0.96	
No screening	 Ref	 Ref	 Ref	 Ref	 Ref	 Ref	 Ref	 Ref	
*Having ≥1 abdominal ultrasound per calendar year 
**Having ≥1 abdominal ultrasound during the study period but less than annually 
NOTE: Adjusted for age, race/ethnicity, Census poverty indicator, year of HCC diagnosis, length of time 
with known cirrhosis, liver etiology, hepatic encephalopathy, NCI comorbidity index score, and some 
provider specialty visited in primary sample. Adjusted for age, race/ethnicity, liver etiology, NCI 
comorbidity index score, and some provider specialty visited in cirrhosis sample. P-value and 95% CI for 
adjusted HR is shown. 
 
4.4 Discussion 
HCC screening receipt and early tumor detection within Milan Criteria at diagnosis is 
associated with overall improved survival in all patients and in patients with known cirrhosis. 
Patients diagnosed with HCC within Milan Criteria survived longer on average compared to 
patients diagnosed with HCC outside of Milan Criteria. Factors associated with early tumor 
detection within Milan Criteria included younger age of diagnosis, female gender, year of HCC 
diagnosis, having longer length of time with known cirrhosis, presence of having other liver 
disease or more than one liver correlated condition, and presence of hepatic encephalopathy, and 
having visited a gastroenterology provider, and having seen a principal provider who was 
employed in the hospital or medical school setting and was trained in the United States.   
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There are noteworthy survival differences when stratified among HCC screening receipt 
groups (consistent screening vs. inconsistent screening vs. no screening).  Longer survival time 
was seen in HCC patients that received consistent screening, followed by HCC patients that 
received inconsistent screening. Results from simple and multivariate logistic regression 
analyses and Cox proportional hazards analyses further confirmed consistent HCC screening was 
the strongest predictor of early tumor detection and subsequently improved overall survival, with 
attenuated benefits seen in those who had undergone inconsistent screening. These findings are 
not surprising and similar to many studies in literature.22,29,30,159 A study by Stravitz and 
colleagues found that the quality of HCC screening was strongly associated with tumor stage at 
diagnosis.30 Roughly 68.7% of patients who received standard-of-care screening, which was 
defined as having received an ultrasound or other abdominal imaging at least once during the 
year prior to HCC diagnosis, were diagnosed within Milan Criteria.30  
Screening benefits are far greater for known cirrhosis patients at risk of developing HCC, 
however surprisingly results from mean survival time in months were equivalent between all 
patients and known cirrhosis patients (30 months vs. 30 months for consistent screening, 23 vs. 
23 months for inconsistent screening respectively). Given cirrhosis patients are highly at risk for 
developing HCC, survival time for known cirrhosis patients were expected to be higher. 
Unfortunately, many patients with cirrhosis do not receive routine HCC screening, which 
Stravitz et al. states may be attributed to differences of opinion among providers regarding cost-
effectiveness and appropriateness of screening.30 Patients with chronic liver disease often remain 
undetected for long periods of time, which could subsequently be a factor of unrecognized 
cirrhosis and low rates of routine HCC screening in this at risk population.65 It is especially 
important that patients diagnosed with cirrhosis receive routine, timely screening for HCC; so 
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curative treatment options are available to patients. Curative treatments for patients with early 
tumor stage are associated with 5-year survival rates close to 70% with liver resection and 
transplantation in comparison to patients with advanced tumor stage.22,45,68  
Screening for HCC is imperative in patients at risk in order to reduce incidence and 
mortality. It is suggested that government health agencies in the United States raise awareness on 
the increasing HCC incidence, as well as adopt HCC screening programs similar to more 
prominent national programs such as the Colorectal Cancer Control Program and the National 
Breast and Cervical Cancer Early Detection Program.160 These programs provide funding to 
various states across the U.S., as well as screening and diagnostic exams to low-income patients 
with little or no health insurance.160 The National Breast and Cervical Cancer Early Detection 
Program also supports education and outreach activities, case management services, and research 
to increase screening rates.160 Increasing awareness through education, outreach activities and 
research concerning the importance of HCC screening and providing the resources necessary for 
HCC screening are critical components in mitigating the growing HCC incidence and mortality 
in the United States. 
According to an evidence-based toolbox and guide to increase preventative screening 
rates in practice by the National Colorectal Cancer Roundtable (NCCRT), studies over two 
decades illustrate that a recommendation from a provider is the most powerful single factor in a 
patient’s decision to be screened for cancer and patients of minority or low-income groups, 
patients with less formal education, and older patients are less likely to be given a screening 
recommendation.161 Patient and provider reminders contribute to increased screening rates, and 
thus it is highly recommended that providers have the necessary resources in the care setting 
such as postcards, letters, and ticklers and logs to remind patients about screening.161 Feedback 
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during staff meetings, monitoring whether documentation procedures require improvement, and 
identifying other needs in the clinical setting are also key in improving cancer screening in the 
practice setting.161 Findings from the second study of this dissertation further support the need to 
address gaps in resources and knowledge surrounding the importance of HCC screening in 
family practice providers. 
HCC is a major cause of mortality in the United States. This study in this dissertation 
reinforces and highlights the importance of a) systematic HCC screening aimed at early tumor 
detection and b) overall improved survival as an effect of early tumor detection and systematic 
HCC screening. The study also underlines the importance of process changes (including 
education, community outreach, funding for continued research etc.) that may help improve 
HCC screening using a large population based, administrative data. 
4.4.1 Limitations 
There are important limitations worth noting. Screen-detected cancer such as HCC is 
subject to lead and length time bias.162 Lead time bias is the amount of time between detection of 
disease and usual clinical presentation or diagnosis, or is defined as the time gained by 
diagnosing the disease using special detection modalities before the patient experiences 
symptoms.156,162 Length time bias is where more slowly growing tumors, with less capability to 
demonstrate it is terminal, may have a longer presymptomatic screen-detectable period and thus 
be more likely to be screen-detected bias.162  
Unfortunately, lead and length time bias could not be ascertained in this study and may 
question the true efficacy of HCC screening and its impact on early tumor detection and overall 
survival. Further, recommendations for HCC screening remain controversial regarding concerns 
surrounding over diagnosis and patient harms cited in other cancer screening programs.163,164 
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HCC screening harms, which have recently been shown to be prevalent and important when 
determining overall value of HCC screening could not be evaluated in this study.   
It is also important to note that although Milan Criteria as a measure of early tumor 
detection has been adopted worldwide, it still remains imperfect. Other tumor staging systems 
including BCLC incorporate liver dysfunction and patient performance status, however these 
characteristics are unfortunately unavailable in SEER-Medicare data.94,96,165 
There was also a large number of missing tumor characteristics data in SEER-Medicare, 
despite imputing similar tumor characteristics available in the PEDSF file. As a result, there 
could be a bias in effect estimates given the sample characteristics could potentially be different 
between patients who had available tumor characteristics vs. patients who did not.166 
4.5 Conclusions 
The third and final study of this dissertation characterizes the association of HCC 
screening receipt with early tumor detection and overall survival in a population based sample of 
patients in the United States. Findings are consistent with literature, as overall improved survival 
and early tumor detection within Milan Criteria at diagnosis is notably associated with more 
HCC screening receipt in this study. There are striking survival differences among HCC 
screening receipt groups (consistent screening vs. inconsistent screening vs. no screening) and 
between patients who are diagnosed with HCC within Milan Criteria in all patients in this study. 
The differences are greater in patients with known cirrhosis.  
In order to alleviate the growing burden in HCC incidence and mortality in the United 
States, awareness through education, outreach activities and research concerning the importance 
of HCC screening should be increased and emphasized. Gaps in resources and knowledge 
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surrounding the importance of HCC screening in family practice providers should be addressed 
in the clinical setting. 
  103 
5. CONCLUSION 
 
This dissertation addresses gaps in the current literature surrounding HCC screening in 
clinical practices from 2003 to 2013 in a racially/ethnic diverse population across the United 
States. It encompasses three components: (1) two improved alternative measurements for HCC 
screening using administrative data, (2) the impact of patient and provider factors on HCC 
screening, and (3) the impact of HCC screening on early tumor detection and overall survival. 
The first study of this dissertation adds to the current literature and suggests improved 
measures to determine HCC screening utilization to reflect society guidelines from American 
Association for the Study of Liver Diseases (AASLD) the and National Comprehensive Cancer 
Network (NCCN). Using the two improved measures to determine HCC screening receipt, HCC 
screening rates were suboptimal and only slightly improved during recent years. In comparison 
to a similar study previously done on patients diagnosed with HCC from 1994 to 2002, roughly 
17% of cirrhotic patients with HCC received consistent screening and 38% received inconsistent 
screening.55 We found that screening rates only increased 1.5% in patients diagnosed with HCC 
from 2003 to 2013 and inconsistent screening increased 15.2%. This study confirms HCC 
remains extremely underutilized in the clinical setting. 
In order to pinpoint potential intervention targets, the second study of this dissertation 
examines patient and provider characteristics that may influence HCC screening receipt. Receipt 
of HCC screening was associated with younger patient age, female gender, being Asian, having 
longer length of time with known cirrhosis, presence of more than one liver correlated condition, 
presence of hepatic encephalopathy, and being seen by a gastroenterologist. Findings were 
somewhat consistent with literature and note the importance of educating family practice 
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providers about HCC screening in at risk patients, given almost all patients saw an internal 
medicine or family practice provider in the 3 years prior to HCC diagnosis. 
The third and final study of this dissertation characterizes the association of HCC 
screening receipt with early tumor detection and overall survival. HCC screening receipt was a 
strong predictor of early tumor detection within Milan Criteria at diagnosis, which was 
subsequently found to be associated with overall improved survival in all patients. Therefore, 
HCC screening is very important, especially in patients diagnosed with cirrhosis. Diagnosis at an 
early stage for HCC is imperative so curative treatment options can be offered to eligible 
patients. 
5.1 Areas for Future Research and Improvement 
Barriers to screening for patients at risk for HCC should be urgently addressed in clinical 
practice. Screening rates are shockingly low for HCC despite countless studies in previous years 
emphasizing underutilization in clinical practice across the United States. Suggestions for future 
research include why screening has not improved in clinical practice in more recent years.  
The findings of this dissertation also highlight the importance of education and awareness 
in HCC screening for internal medicine and family practice providers. Misconceptions regarding 
HCC screening by family practice providers subsequently lead to profound underutilization of 
HCC screening. Courses or seminars to inform family practice providers and staff regarding the 
importance of referrals to gastroenterologists or hepatologists are imperative. In this study, 
receipt of any HCC screening was associated with having been seen by a gastroenterologist and 
further support the need for patients to be referred to a gastroenterology or hepatology specialist 
by internal medicine or family practice providers. 
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Similarly, improved awareness surrounding HCC screening for internal medicine or 
family practice providers using fact sheets, posters and other media outlets which review the 
most effective screening modality and how often to screen for HCC are critical in improving 
HCC screening rates. Many family practice providers have reported feeling responsible for HCC 
screening, yet are unaware of how to best perform screening for HCC. A recommendation from a 
provider is the most powerful single factor in a patient’s decision to be screened for cancer and 
thus awareness and education is again, critical in improving HCC screening rates to mitigate the 
growing incidence and mortality. 
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APPENDIX 
 
Supplementary Figures 
 
Figure 13A. Survival estimates for all patients by receipt of HCC screening after applying 
algorithm intent (n=13,714) 
 
Consistent Screening=Having ≥1 abdominal ultrasound per calendar year 
Inconsistent Screening=Having ≥1 abdominal ultrasound during the study period but less than annually 
This figure illustrates survival estimates with 95% confidence interval bands among all patients 
diagnosed with HCC from the years of 2003 to 2013 who received consistent, inconsistent and no 
screening in the 3 years prior to their HCC diagnosis after algorithm intent. 
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Figure 14A. Survival estimates for known cirrhosis patients by receipt of HCC screening after 
applying algorithm intent (n=2,972) 
 
Consistent Screening=Having ≥1 abdominal ultrasound per calendar year 
Inconsistent Screening=Having ≥1 abdominal ultrasound during the study period but less than annually 
This figure illustrates survival estimates with 95% confidence interval bands among known cirrhosis 
patients diagnosed with HCC from the years of 2003 to 2013 who received consistent, inconsistent and no 
screening in the 3 years prior to their HCC diagnosis after algorithm intent. 
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Supplementary Tables 
 
 
Table 7A. Estimation results for predictors of change in HCC screening receipt using a 
generalized ordered logistic regression model (n=13,714) 
 Adjusted OR 
(Standard 
Error) 
P-value Adjusted OR 
(Standard 
Error) 
P-value 
 Consistent Screening* Inconsistent Screening** 
Age of HCC 
diagnosis  
1.05 (0.004) 0.19 1.07 (0.03) <0.001 
Gender 
Male Ref Ref Ref Ref 
Female 0.97 (0.07) 0.69 0.91 (0.04) 0.04 
Race/ethnicity 
White Ref Ref Ref Ref 
Black 0.85 (0.11) 0.22 0.84 (0.06) 0.01 
Hispanic 0.76 (0.08) 0.007 0.74 (0.05) <0.001 
Asian 0.25 (0.03) <0.001 0.47 (0.03) <0.001 
Other race 0.39 (0.06) <0.001 0.64 (0.06) <0.001 
Year of HCC diagnosis 
2003 Ref Ref Ref Ref 
2004 1.10 (0.25) 0.67 1.01 (0.11) 0.95 
2005 1.41 (0.32) 0.13 0.94 (0.10) 0.55 
2006 1.30 (0.28) 0.21 1.10 (0.12) 0.40 
2007 1.19 (0.24) 0.38 1.05 (0.11) 0.63 
2008 1.57 (0.33) 0.03 1.18 (0.12) 0.11 
2009 1.73 (0.36) 0.01 1.21 (0.12) 0.06 
2010 0.97 (0.19) 0.86 1.12 (0.12) 0.25 
2011 1.13 (0.22) 0.55 0.15 (0.12) 0.18 
2012 1.12 (0.22) 0.57 0.12 (0.11) 0.25 
2013 0.74 (0.14) 0.11 1.20 (0.12) 0.08 
Cirrhosis duration 
No diagnosis of 
cirrhosis 
Ref Ref Ref Ref 
Cirrhosis diagnosis 
within 3 years of 
HCC diagnosis 
0.33 (0.04) <0.001 0.37 (0.02) <0.001 
Cirrhosis before 3 
year screening 
period 
0.19 (0.02) <0.001 0.52 (0.03) <0.001 
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Table 7A. Continued 
 Adjusted OR 
(Standard 
Error) 
P-value Adjusted OR 
(Standard 
Error) 
P-value 
HCC etiology 
No liver correlated 
conditions 
Ref Ref Ref Ref 
HBV 0.82 (0.12) 0.18 0.98 (0.05) 0.71 
HCV 0.61 (0.13) 0.02 0.77 (0.09) 0.03 
Alcoholic fatty liver 
or alcoholic 
cirrhosis 
0.93 (0.16) 0.68 1.02 (0.10) 0.85 
Other liver disease 0.46 (0.06) <0.001 0.46 (0.04) <0.001 
More than one liver 
correlated condition 
0.44 (0.05) <0.001 0.56 (0.04) <0.001 
Ascites 
Yes 0.98 (0.10) 0.81 0.62 (0.05) <0.001 
No Ref Ref Ref Ref 
Hepatic encephalopathy 
Yes 0.69 (0.06) <0.001 0.72 (0.06) <0.001 
No Ref Ref Ref Ref 
NCI comorbidity index score 
None Ref Ref Ref Ref 
Low 0.58 (0.27) 0.25 0.94 (0.09) 0.53 
Moderate 0.62 (0.29) 0.31 0.88 (0.09) 0.21 
High 0.53 (0.25) 0.17 0.75 (0.07) 0.004 
Provider specialty visited 
Internal medicine/ 
family practice 
0.48 (0.13) 0.005 0.54 (0.05) <0.001 
Gastroenterology 0.31 (0.04) <0.001 0.42 (0.02) <0.001 
Hematology/ 
oncology 
1.04 (0.09) 0.60 0.85 (0.04) 0.002 
Vascular/ 
interventional 
radiology 
0.35 (0.10) <0.001 0.32 (0.03) <0.001 
General surgery 0.86 (0.07) 0.06 0.79 (0.04) <0.001 
Other 0.58 (0.17) 0.07 0.66 (0.06) <0.001 
Practice arrangement of principal provider 
Solo practice Ref Ref Ref Ref 
Group practice 1.12 (0.09) 0.18 1.10 (0.05) 0.05 
Hospital 0.96 (0.14) 0.79 1.24 (0.10) 0.01 
Medical school 0.60 (0.17) 0.08 1.16 (0.25) 0.50 
Other 1.00 (0.13) 0.97 1.12 (0.08) 0.13 
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Table 7A. Continued 
 Adjusted OR 
(Standard 
Error) 
P-value Adjusted OR 
(Standard 
Error) 
P-value 
U.S. training status of principal provider 
Yes 1.02 (0.08) 0.84 1.12 (0.05) 0.01 
No Ref Ref Ref Ref 
Other 1.01 (0.28) 0.97 1.04 (0.15) 0.80 
Constant 1862.24 
(1298.90) 
<0.001 8.21 (1.94) <0.001 
*Having ≥1 abdominal ultrasound per calendar year 
**Having ≥1 abdominal ultrasound during the study period but less than annually 
†Reference screening category were patients with no screening 
 
 
Table 10A. Results from multivariate logistic regression model assessing HCC screening receipt 
on Milan Criteria after applying algorithm intent (Diagnosis years 2003 to 2013) 
 Primary sample (n=13,714)	 Cirrhosis sample (n=2,972)	
 Crude 
OR	
Adjusted 
OR	
P-
value†	
95% 
CI†	
Crude 
OR	
Adjusted 
OR	
P-
value†	
95% 
CI†	
Consistent 
screening*	
6.33	 3.02	 <0.001	 2.29-
4.00	
3.46	 2.99	 <0.001	 2.12-
4.21	
Inconsistent 
screening**	
3.27	 1.75	 <0.001	 1.58-
1.94	
1.92	 1.67	 <0.001	 1.42-
1.97	
No 
screening	
Ref	 Ref	 Ref	 Ref	 Ref	 Ref	 Ref	 Ref	
*Having ≥1 abdominal ultrasound per calendar year 
**Having ≥1 abdominal ultrasound during the study period but less than annually 
†For adjusted OR results 
NOTE: Adjusted for age, gender, year of HCC diagnosis, length of time with known cirrhosis, liver 
etiology, hepatic encephalopathy, some provider specialty visited, practice arrangement of principal 
provider, and U.S. training status in primary sample. Adjusted for gastroenterology provider visited and 
practice arrangement of principal provider only in cirrhosis sample. 
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Table 11A. Full results from adjusted logistic regression model in all patients assessing HCC 
screening receipt on Milan Criteria after applying algorithm intent (Diagnosis years 2003 to 
2013; n=13,714) 
 Adjusted OR	 P-value	 95% CI	
Screening group 
Consistent screening*	 3.02	 <0.001	 2.29-4.00	
Inconsistent screening**	 1.75	 <0.001	 1.58-1.94	
No screening	 Ref	 Ref	 Ref	
Age of HCC diagnosis 0.98 <0.001 0.98-0.99 
Gender 
Male	 Ref Ref Ref 
Female	 1.14 0.002 1.05-1.24 
Year of HCC diagnosis 
2003	 Ref Ref Ref 
2004	 1.81 <0.001 1.45-2.26 
2005	 1.71 <0.001 1.38-2.14 
2006	 1.66 <0.001 1.34-2.07 
2007	 1.59 <0.001 1.27-1.96 
2008	 1.70 <0.001 1.37-2.08 
2009	 1.64 <0.001 1.33-2.02 
2010	 2.11 <0.001 1.71-2.59 
2011	 1.91 <0.001 1.56-2.35 
2012	 1.90 <0.001 1.55-2.33 
2013	 2.13 <0.001 1.74-2.61 
Cirrhosis duration 
No diagnosis of cirrhosis	 Ref Ref Ref 
Cirrhosis diagnosis within 3 years 
of HCC diagnosis	
2.03 <0.001 1.83-2.26 
Cirrhosis before 3 year screening 
period	
2.08 <0.001 1.85-2.35 
HCC etiology 
No liver correlated conditions	 Ref Ref Ref 
HBV	 1.00 0.97 0.90-1.11 
HCV	 1.20 0.11 0.96-1.50 
Alcoholic fatty liver or alcoholic 
cirrhosis	
1.17 0.09 0.97-1.41 
Other liver disease 1.26 0.002 1.09-1.46 
More than one liver correlated 
condition	
1.10 <0.001 01.00-1.20 
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Table 11A. Continued 
 Adjusted OR	 P-value	 95% CI	
Hepatic encephalopathy 
Yes 1.27 0.001 1.10-1.45 
No Ref Ref Ref 
Provider specialty visited 
Internal medicine/ family practice	 0.84 0.020 0.73-0.97 
Gastroenterology	 1.31 <0.001 1.20-1.43 
Practice arrangement of principal provider 
Solo practice	 Ref Ref Ref 
Group practice	 1.03 0.49 0.95-1.12 
Hospital	 1.10 0.23 0.94-1.28 
Medical school	 1.43 0.06 0.98-2.10 
Other	 1.02 0.80 0.89-1.17 
U.S. training status of principal provider 
Yes 1.14 0.003 1.04-1.24 
No Ref Ref Ref 
Other 1.21 0.17 0.92-1.58 
Constant 0.52 0.001 0.36-0.77 
*Having ≥1 abdominal ultrasound per calendar year 
**Having ≥1 abdominal ultrasound during the study period but less than annually 
 
 
Table 11B. Full results from adjusted logistic regression model in known cirrhosis patients 
assessing HCC screening receipt on Milan Criteria (Diagnosis years 2003 to 2013; n=2,972) 
 Adjusted OR	 P-value	 95% CI	
Screening group 
Consistent screening*	 2.47	 <0.001	 1.92-3.18	
Inconsistent screening**	 1.73	 <0.001	 1.43-2.10	
No screening Ref Ref Ref 
Provider specialty visited 
Gastroenterology	 1.63 <0.001 1.36-1.96 
Practice arrangement of principal provider 
Solo practice	 Ref Ref Ref 
Group practice	 1.16 0.08 0.98-1.37 
Hospital	 1.22 0.19 0.91-1.63 
Medical school	 2.60 0.01 1.24-5.45 
Other	 1.30 0.06 0.99-1.70 
Constant 0.48 <0.001 0.39-0.59 
*Having ≥1 abdominal ultrasound per calendar year 
**Having ≥1 abdominal ultrasound during the study period but less than annually 
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Table 12A. Mean survival time in months for all HCC patients by screening groups after 
applying algorithm intent (n=13,714) 
 Mean time survived in months 
(Standard Error) 
Consistent screening* 32.9 (1.98) 
Inconsistent screening** 30.1 (0.85) 
No screening 17.6 (0.28) 
*Having ≥1 abdominal ultrasound per calendar year 
**Having ≥1 abdominal ultrasound during the study period but less than annually 
 
 
 
 
 
 
 
Table 13A. Mean survival time in months for known cirrhosis HCC patients by screening groups 
after applying algorithm intent (n=2,972) 
 Mean time survived in months 
(Standard Error) 
Consistent screening* 32.1 (2.35) 
Inconsistent screening** 28.4 (1.18) 
No screening 17.4 (0.62) 
*Having ≥1 abdominal ultrasound per calendar year 
**Having ≥1 abdominal ultrasound during the study period but less than annually 
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Table 14A. Full results from Cox proportional hazards model in all HCC patients for association 
with screening receipt and overall survival (Diagnosis years 2003 to 2013; n=13,714) 	 Adjusted HR	 P-value	 95% CI	
Screening group	
Consistent screening*	 0.72	 <0.001	 0.66-0.78	
Inconsistent 
screening**	
0.84	 <0.001	 0.81-0.88	
No screening	 Ref	 Ref	 Ref	
Age of HCC diagnosis	 1.02	 <0.001	 1.01-1.02	
Race/ethnicity	
White	 Ref	 Ref	 Ref	
Black	 1.03	 0.37	 0.97-1.10	
Hispanic	 0.97	 0.26	 0.92-1.02	
Asian	 0.77	 <0.001	 0.72-0.83	
Other race	 0.78	 <0.001	 0.72-0.84	
Census poverty indicator	
0%-<5% poverty	 Ref	 Ref	 Ref	
5% to <10% poverty	 1.05	 0.07	 1.00-1.11	
10% to <20% poverty	 1.07	 0.02	 1.01-1.12	
20% to 100% poverty	 1.18	 <0.001	 1.12-1.25	
Year of HCC diagnosis	
2003	 Ref	 Ref	 Ref	
2004	 0.93	 0.13	 0.85-1.02	
2005	 0.91	 0.04	 0.83-1.00	
2006	 0.85	 0.001	 0.77-0.93	
2007	 0.84	 0.001	 0.77-0.92	
2008	 0.86	 0.001	 0.79-0.94	
2009	 0.83	 <0.001	 0.76-0.91	
2010	 0.77	 <0.001	 0.71-0.85	
2011	 0.78	 <0.001	 0.71-0.85	
2012	 0.84	 <0.001	 0.77-0.92	
2013	 0.87	 0.004	 0.77-0.96	
Cirrhosis duration	
No diagnosis of 
cirrhosis	
Ref	 Ref	 Ref	
Cirrhosis diagnosis 
within 3 years of HCC 
diagnosis	
1.00	 0.95	 0.95-1.05	
Cirrhosis before 3 year 
screening period	
0.96	 0.18	 0.90-1.02	
 
 
  136 
 
 
 
 
 
Table 14A. Continued 	 Adjusted HR	 P-value	 95% CI	
HCC etiology	
No liver correlated 
conditions	
Ref	 Ref Ref 
HBV	 0.87	 <0.001	 0.83-0.91	
HCV	 0.94	 0.27	 0.84-1.05	
Alcoholic fatty liver or 
alcoholic cirrhosis	
0.94	 0.21	 0.86-1.03	
Other liver disease	 0.87	 <0.001	 0.81-0.93	
More than one liver 
correlated condition	
0.91	 0.001	 0.86-0.96	
Ascites	
Yes	 1.32	 <0.001	 1.24-1.41	
No	 Ref	 Ref	 Ref	
NCI comorbidity index score	
None	 Ref	 Ref	 Ref	
Low	 1.08	 0.04	 1.00-1.17	
Moderate	 1.12	 0.005	 1.04-1.21	
High	 1.41	 <0.001	 1.30-1.52	
Provider specialty seen	
Gastroenterology	 0.79	 <0.001	 0.76-0.82	
Vascular/ 
interventional 
radiology	
0.86	 <0.001	 0.82-0.91	
Practice arrangement	
Solo practice	 Ref	 Ref	 Ref	
Group practice	 1.00	 0.88	 0.96-1.04	
Hospital	 0.95	 0.18	 0.89-1.02	
Medical school	 0.86	 0.13	 0.71-1.04	
Other	 1.02	 0.58	 0.95-1.09	
*Having ≥1 abdominal ultrasound per calendar year 
**Having ≥1 abdominal ultrasound during the study period but less than annually 
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Table 14B. Full results from Cox proportional hazards model in known cirrhosis HCC patients 
for association with screening receipt and overall survival (Diagnosis years 2003 to 2013; 
n=2,972) 
 Adjusted HR P-value 95% CI 
Screening group 
Consistent screening* 0.73 <0.001 0.64-0.82 
Inconsistent screening** 0.87 0.005 0.80-0.96 
No screening Ref Ref Ref 
Age of HCC diagnosis 1.02 <0.001 1.01-1.02 
Race/ethnicity 
White Ref Ref Ref 
Black 1.06 0.42 0.92-1.21 
Hispanic 0.93 0.17 0.84-1.03 
Asian 0.67 <0.001 0.58-0.78 
Other race 0.69 <0.001 0.58-0.83 
Ascites 
Yes 1.22 <0.001 1.12-1.34 
No Ref Ref Ref 
Hepatic encephalopathy 
Yes 1.11 0.03 1.01-1.23 
No Ref Ref Ref 
Provider specialty seen 
Gastroenterology 0.73 <0.001 0.67-0.81 
*Having ≥1 abdominal ultrasound per calendar year 
**Having ≥1 abdominal ultrasound during the study period but less than annually 
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Table 14C. Summary results from Cox proportional hazards model for association with 
screening receipt and overall survival after algorithm intent (Diagnosis years 2003 to 2013) 
 Primary sample (n=13,714)	 Cirrhosis sample (n=2,972)	
	 Crude 
HR	
Adjusted 
HR	
P-value	 95% CI	 Crude 
HR	
Adjusted 
HR	
P-value	 95% CI	
Consistent 
screening*	
0.54	 0.63	 <0.001	 0.55-
0.72	
0.55	 0.59	 <0.001	 0.50-
0.70	
Inconsistent 
screening**	
0.64	 0.73	 <0.001	 0.69-
0.77	
0.67	 0.72	 <0.001	 0.66-
0.79	
No 
screening	
Ref	 Ref	 Ref	 Ref	 Ref	 Ref	 Ref	 Ref	
*Having ≥1 abdominal ultrasound per calendar year 
**Having ≥1 abdominal ultrasound during the study period but less than annually 
NOTE: Adjusted for age, race/ethnicity, Census poverty indicator, year of HCC diagnosis, length of time 
with known cirrhosis, liver etiology, hepatic encephalopathy, NCI comorbidity index score, and some 
provider specialty visited in primary sample. Adjusted for age, race/ethnicity, liver etiology, NCI 
comorbidity index score, and some provider specialty visited in cirrhosis sample. P-value and 95% CI for 
adjusted HR is shown. 
 
